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ABSTRACT 
 
Computational modeling approaches have lately been earning their place as viable tools 
in drug discovery. Research efforts more often include computational component and the usage 
of the scientific software is commonplace at more stages of the drug discovery pipeline. 
However, as software takes on more responsibility and the computational methods grow more 
involved, the gap grows between research entities that have the means to maintain the necessary 
computational infrastructure and those that lack the technical expertise or financial means to 
obtain and include computational component in their scientific efforts. To fill this gap and to 
meet the need of many, mainly academic, labs numerous community contributions collectively 
known as open source projects play an increasingly important role. This work describes design, 
implementation and application of a set of drug discovery workflows based on the CHARMMing 
(CHARMM interface and graphics) web-server. The protocols described herein include docking, 
virtual target screening, de novo drug design, SAR/QSAR modeling as well as chemical 
education. The performance of the newly developed workflows is evaluated by applying them to 
a number of scientific problems that include reproducibility of crystal poses of small molecules 
in protein-ligand systems, identification of potential targets of a library of natural compounds as 
well as elucidating molecular targets of a vitamin. The results of these inquiries show that 
protocols developed as part of this effort perform comparably to commercial products, are able 
to produce results consistent with the experimental data and can substantially enrich the research 
efforts of labs with otherwise little or no computational component
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CHAPTER ONE: 
INTRODUCTION 
The Need for Web-Based Open Source Drug Discovery Platforms 
 The concept of open source application development has emerged with the popularization 
of the World Wide Web as a platform for technical and scientific collaboration. The ability to 
communicate, share ideas and individual contributions to achieve a single objective gave rise to 
group efforts where each participant could advance the common goal independent of their 
physical location, affiliation or even technical background. Such a concept promotes the 
participation of people that while having a wide range of skills have a common set of interests or 
even passions. This allows the participants to contribute “freely”, often without an expectation of 
monetary reimbursement purely for the sake of advancing the field and serving the community of 
people with similar interests. The motivation behind such undertakings is especially strong when 
the project contributes to satisfying a need of significant importance, a need that would be 
difficult to meet without such a collective effort. 
Drug discovery is a field where, at first glance, such an open community effort is an 
unlikely approach. Historically the cost and effort of developing a new drug has largely confined 
successes to large pharmaceutical companies or otherwise well-funded research institutions.
1
 
Development and use of computer aided drug design (CADD) techniques has provided numerous 
benefits to the overall process and has been acknowledged by the award of the Noble Prize in 
Chemistry in 2013.
2
 However the expertise required to create powerful commercial software 
packages has resulted in high licensing costs,
3,4
 thus limiting access to academic groups. 
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Fortunately, this trend has started to shift with the emergence of freely available software such, 
as Autodock
5
 and several other packages,
4
 largely developed by the academic computational 
chemistry community. However, for the most part, these software packages require familiarity 
with CADD methodologies and are better suited for computer savvy users that are at least 
comfortable if not familiar with the computational component of drug discovery.
6
 This has 
hampered the proliferation of CADD tools into less computationally minded drug discovery labs. 
The need for intuitive and easy to use CADD solutions has largely been met by the commercial 
software companies such as Accelrys, Schrödinger, and others that have incorporated full 
featured graphical user interfaces (GUI) into their programs.
7–9
 However, as alluded to above, the 
cost of these packages is typically prohibitive to academic groups and/or institutions. Further, it 
has proven increasingly difficult to strike a balance between software that is user-friendly yet 
incorporates a wide range of advanced functionality and customizability. Another aspect of 
concern is portability. For example stand-alone software that requires local installation on every 
computer, may find less use in today’s world1 where researchers expect both the application and 
the data to be accessible from any machine on any platform from any location.
10
  
Another hurdle, faced by the non-expert, to incorporating computational modeling into 
drug discovery efforts is the difficulty of obtaining reliable small molecule parameters.
11–13
 Most 
widely used and well tested force fields have been developed with proteins and nucleic acids 
rather than small molecules in mind
14
. Until recently this has meant that drug-like molecule 
parameters have been less reliable, with assignment often arbitrary. Lately, however, there has 
been a significant amount of effort devoted to improving the reliability of small molecule 
parameters and developing efficient protocols to generate them for a much greater and more 
diverse chemical space
11,12,14,15
. 
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The applications development of which is described in this work have been designed with 
several criteria in mind: 
1. Incorporation of a range of drug discovery methods to aid researchers at different 
points in the drug discovery process. Such methods include molecular modeling and 
simulations, docking, de-novo drug design and chemoinformatics.  
2. All the data produced by the applications or uploaded by the user remains accessible 
indefinitely and is tied to the user account and secured by the verification of login 
credentials. All the jobs run independently and do not require active user session. The 
results of user jobs along with all the input and output file are stored in the database 
and are available for access at any time in the future.  
3. Pre-loaded public compound library is available for docking and virtual screening 
jobs in addition to user supplied compounds. 
4. Integration with outside resources such as protein, compound and assay data 
repositories. 
5. Usable by computational novices and advanced users alike. 
Primary users targeted by the application include small academic labs and any other labs 
that don’t have financial means of obtaining commercial drug discovery packages or don’t have 
the expertise to run and maintain drug discovery applications without having access to 
computational core facilities. Some more specific examples of potential users are: 
 Medicinal chemistry lab that would like to use computational techniques at early stages 
of discovery to get lead ideas 
 An experimental lab that would like to supplement their findings with additional rationale 
based on computational methods 
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 A group that would like to build hypothesis for lead optimization using a set of already 
obtained experimental data 
 
Challenges of Open Source Projects 
 Open source approach to developing drug discovery applications has a number of 
challenges. Some are inherent to the concept of open source approach itself while others are 
more specific to the field of computer - aided drug discovery. The very nature of collaborative 
open source projects means that there are multiple contributors. Aside from the more obvious 
factors such as different geographical locations, which internet more or less successfully 
alleviates, there are other issues to consider. It is likely that there may be significant differences 
between technical backgrounds of the contributors. Since in this case the project largely deals 
with computer programming, the most evident manifestation of these differences may be the 
variety of programming languages and development paradigms the contributors may be 
comfortable with. This presents a two-fold challenge. First, at the earliest stages of the project 
some common coding framework should be chosen such that new contributors find it easy 
enough to transition to it even if they come from a different background or in general have less 
advanced technical skills. Second, as the project progresses the coding standards should be 
adhered to and kept within the common framework. The most obvious benefits of these steps 
will be the fact that a new developer will be able to get up to speed quickly, will be able to read 
and understand the code of other developers, and most importantly will be able to follow the 
same design and coding patterns. This will help prevent the project from becoming too 
fragmented over time, allow participants to better integrate their individual contributions into the 
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overall project as well as make maintenance and upgrades easier. The latter is especially 
important for open-source community efforts as the contributor turnover is usually high. 
 Another largely technical aspect of any open-source effort is the platforms. In this context 
platform encompasses such concepts as computer architecture and operating system. Both the 
platform on which the development is done and on which the final product is served to the end-
user are important. Even though most programming languages or development frameworks strive 
to be platform-independent, in practice platform differences may pose challenges ranging from 
syntax differences to binaries or compiler incompatibilities. Similarly, packaging a final product 
as a Windows® executable will likely mean that it will not execute on a Linux based machine. 
The end-user platform consideration is particularly sensitive in the age of mobile computing 
where users expect their applications served on wide variety of mobile devices. 
 The issue of data and information standards is also an important consideration when it 
comes to open-source efforts and it is by no means unique to the field of CADD. However in the 
context of this work it is proper to consider cases specific to drug discovery, storage and 
representation of chemical information. A wide variety of structural data formats makes for an 
important consideration when designing an open-source application whose functionality largely 
hinges on the ability to process chemical structural information. In principle, suitable plfug-ins 
can over time be developed by community contributors to allow the application to speak any 
dialect of a chemical language. However a project whose success depends on the community’s 
acceptance risks alienating its users if a basic support for most common formats is not provided 
from the beginning. Another aspect that, to a degree, deals with standards is compatibility with 
other commercial, free or open-source tools available to the community. CADD is a large and 
growing field. Computer techniques find use in many stages of the drug discovery process 
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ranging from hit finding to lead optimization, toxicology predictions and beyond. In addition 
there may be multiple computational approaches or software applications to perform similar 
tasks. With this in mind the open-source application has to be able to both accept as input and 
produce the output compatible with other programs that the user may potentially utilize as part of 
their research. 
 A more practical aspect of developing a scientific application is its ability to crunch a lot 
of data fast. In other words, performance is very important consideration. From running an 
extended molecular dynamics simulation on a many atom system to virtually screening a large 
compound library, the application has to be able to perform such computationally intensive tasks 
in a reasonable time. In addition the execution pattern has to be able to take advantage of 
common multi-processor or high performance computing (HPC) architectures in order to spread 
the computational load among many worker threads. 
 Another important point to consider when developing an open source application is its 
ability to be expanded, deployed on outside resources or adopted for a particular need. The level 
of difficulty associated with these tasks would directly correlate with the application’s pool of 
willing contributors and its ability to serve as the basis for independent projects. 
 Finally, the most important aspect of developing any scientific application is the 
soundness of the methods that it implements and an ability to reasonably validate the results that 
it produces. The CADD community is a growing one and there is no shortage of contributors of 
methods in many of its areas. This is a coin of two sides however; as there is a choice of quality 
methods developed and peer reviewed on one side and the challenge of integrating this diversity 
of methods and tasks into a cohesive workflow. The latter represents a particular challenge and 
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in addition to addressing the above challenges is one of the primary foci of the work presented in 
this manuscript. 
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CHAPTER TWO: 
DEVELOPMENT OF THE CHARMMING WEB USER INTERFACE AS A PLATFORM 
FOR COMPUTER-AIDED DRUG DESIGN 
 
Note to Reader 
 Reprinted (adapted) with permission from Yuri Pevzner 
†
, Emilie Frugier 
‡
, Vinushka 
Schalk 
†§
, Amedeo Caflisch 
‡
, and H. Lee Woodcock 
*† 
Journal of Chemical Information and 
1
Modeling 2014, 54, 2612-2620 Copyright 2014 American Chemical Society 
 The publication follows; supporting information can be found in Appendix A. 
 CHARMM Interface and Graphics Platform  
The CHARMM interface and graphics (CHARMMing)
1
 is an open source Web interface 
to the popular macromolecular modeling package CHARMM.
2,3
 The goal of the CHARMMing 
project is to provide a platform-independent Web-based front-end that allows its users to set up 
and perform a wide variety of molecular modeling tasks. At its inception CHARMMing project 
was designed to satisfy some of the unmet needs of the drug discovery community as well as 
address a number of the implementation challenges mentioned in chapter one. CHARMMing is 
built using Django
4
 framework which is based on a widely used Python
5
 scripting language. 
                                                          
†
 Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE205, Tampa, 
Florida 33620-5250, United States 
‡
 Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland 
§
 Department of Natural Sciences, New College of Florida, Sarasota, Florida 34243, United 
States 
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Python is a high level language that is relatively easy to learn even for somebody with limited 
exposure to programming while at the same time is adherent to the more advanced object-
oriented programming principles. At the same time Django uses a consistent model-view 
paradigm that facilitates consistency of the code structure and makes it easy to add and 
effectively encapsulate new features, modules and functionality. Although Django uses a 
relational database (MySQL
6
 in the context of this project) as a back-end storage engine, 
database access is facilitated via an intuitive ORM (object-relational mapping) API (application 
program interface) that allows database operations to be performed even by developers with no 
knowledge of SQL (Structured Query Language) that is natively used to operate on relational 
databases. The use of above technologies makes contribution to CHARMMing project possible 
from a variety of platforms. Moreover the end product of the project is a web-based application. 
This means that the end-user functionality is served via a web browser, thus eliminating the 
issues of cross-platform compatibility as modern browsers are able to serve content rather 
consistently over a wide range of computer architectures, operating systems and devices. 
CHARMMing’s basic functionality includes structure processing, setting up and running 
molecular dynamics simulation and other molecular modeling tasks. It directly interfaces with 
PDB (Protein Data Bank)
7
 to retrieve structures and includes an internal parser and structure 
processing mechanism to prepares biological systems of interest for molecular modeling studies. 
CHARMMing’s infrastructure includes PBS (Portable Batch System)8 for scheduling of jobs 
submitted by multiple users and the jobs’ distribution over available HPC resources. 
CHARMMing’s users range from small academic labs, that benefit from the portal’s 
functionality, to educators, that include molecular modeling in their curricula and use the portal 
to facilitate their teaching.
9–11
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CHARMMing is open source and the code can be downloaded for free. In addition 
CHARMMing comes with an automated installer that can be used to install an instance of 
CHARMMing infrastructure and the interface on a Linux based architecture. This is particularly 
useful when developing a custom and possibly proprietary application using CHARMMing with 
all or some of its functionality as a starting point. The development of the VTS (Virtual Target 
Screening)
12
 server described later in this work is an example of such use of CHARMMing. The 
remainder of this chapter describes the development and evaluation of fragment-based docking 
protocol as an extension of CHARMMing functionality. 
 
Fragment-based docking protocol in CHARMMing 
Implementation Details 
Target Preparation 
Target proteins begin their preparation via CHARMMing’s structure submission section. 
Here, tasks such as the addition of hydrogens, identification of any non-protein moieties, and 
assignment of final parameters are carried out (using the latest, CHARMM36 protein force 
field).
13,14
 Co-crystallized small molecules (i.e., ligands) are automatically parameterized using 
the CGenFF.
15
 Specifically, ligand atom-typing and parameterization is performed by 
sequentially attempting several automated parameterization tools. The default order is: (1) 
Param-Chem,
15–17
 (2) MATCH,
18
 (3) Antechamber,
19
 and (4) GENRTF.
20
 As an alternative to 
the default order a user can specify the exact build procedure to use for parameterization. 
  
Compound Library and Ligand Upload 
CHARMMing docking module provides a pre-loaded library of drug-like compounds for 
12 
 
virtual screening experiments. The library consists of approximately 8,000 molecules from the 
Maybridge Hitfinder
TM
 set (www.maybridge.com). All of the provided molecules have been 
atom typed according to CGenFF convention to comply with CHARMM requirements and 
confirmed to decompose into at least 3 sufficiently sized fragments to meet the fragment-based 
docking criteria. CHARMMing also allows users to upload ligands by providing a coordinate file 
in mol2 format. Upon uploading, the ligand undergoes atom-typing and parameterization as 
previously described. The ligand and corresponding parameter, topology, and structure files are 
then saved on disk as well as cataloged in the database. The parameters for pre-loaded and user-
uploaded ligands contain penalty scores that reflect the quality of the bonded parameters and 
partial charges.
17
 These penalties should be used by the user to make decisions regarding 
compounds that should be discarded due to the lack of quality parameters. Unlike the pre-loaded 
compound library, any user-uploaded ligands are restricted to their account only and are not 
visible to other users. The user is also given the ability to create custom sets of molecules based 
on any pre-loaded or user uploaded compounds. This can be done via the “Ligand Sets” section 
(Figure 1) of the docking module. Any custom or pre-loaded set can be docked in its entirety or 
by selecting individual molecules on the docking submission page (Figure 2). 
 
Binding Site Definition 
To provide maximum flexibility with respect to job setup, two different ways of 
specifying the binding region of interest are implemented. The first approach identifies the 
binding pocket using the position of a co-crystallized ligand that may be present. In this case, 
when launching a docking job a user is presented with a list of all co-crystallized small  
13 
 
 
Figure 1. The “Ligand Set Details” page allows the user to manage custom ligand sets. The user 
can define and describe a custom ligand set as well as add ligands to it from any of the other sets 
including the pre-loaded public library. 
 
molecules along with their 2D structural representations. Once the desired small molecule is 
chosen, the binding site is defined via proximity to the aforementioned small molecule. In cases 
where no co-crystallized ligand is present, or if a user simply wishes to investigate alternative 
binding sites, we have implemented an interactive and graphical binding site definition tool 
(Figure 3). To use this tool, two residues should be selected that roughly correspond to the edges  
14 
 
 
Figure 2. The “Submit Docking Job” page. This page presents the user with the ability to select 
the target coordinates for docking, define the binding pocket (vide infra), and select ligands to 
dock from the list of available small molecules. The native ligands and ligands available for 
docking can be visualized in 3D using the embedded visualization application. 
 
of the desired binding region. The midpoint between these residues is then determined and 
defined as the approximate center of the binding site. Based on a user-defined radius, a list of all 
residues within this distance is compiled and both visually highlighted and presented as a list. 
The user can then add or remove residues to/from this list by either modifying the text of the 
residue list, changing the specified search radius, or modifying it via graphical selection (i.e., 
clicking). Ultimately, all user-defined binding sites are saved and presented as options, with any 
existing co-crystallized ligands, at the docking job setup page. 
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Figure 3. The binding site definition page. This page provides the user with multiple ways to 
select a custom binding site. This can be done either by manually typing in the residue numbers, 
graphically selecting residues, or defining the centroid and specifying the radius in Å. 
 
Docking Protocol 
Docking algorithms used in this protocol are based on the popular grid-based paradigm, 
used by most current docking programs.
21–26
 In this approach the solvent accessible surface area 
of the target and the ligand as well as the target’s binding site are discretized onto a 3D lattice. 
The lattice then either stores information about the atoms enclosed by a cubic unit of the grid or 
contains the potential contributions projected onto the grid’s vertices. Pre-computed grids allow 
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for efficient calculation of both van der Waals and electrostatic contributions to the scoring 
function, facilitating rapid evaluation of ligand placements within the binding site. 
 The docking procedure consists of several steps where different programs perform 
distinct tasks. To streamline the communication between the programs and ensure compatibility 
of input and output data a series of scripts were written in Python, Perl, and Linux shell scripting 
languages. The OpenBabel
27
 file conversion utility was used to inter-convert between different 
representations of the protein and compound structures. The program MATCH30 was used to 
generate CGenFF compatible topologies and parameters. The fragment-based docking protocol 
implemented in CHARMMing is outlined in Figure 4 and described below: 
1.  Each compound to be docked is first broken down into fragments. A fingerprint 
describing chemical richness is generated for each fragment and its parent compound. 
The three most chemically rich, but not necessarily different, fragments are identified to 
serve as anchors for docking. These steps are carried out by the program DAIM 
(Decomposition and Identification of Molecules).
28
 
 
2.  The user then identifies the binding site to be used in the docking job. All non-
protein, non-solvent compounds present in the submitted target structure are displayed on 
the “Submit Docking Job” page (Figure 2). Based on the user selected compound, the 
proximal residues are identified and the binding site defined. 
3.  The previously identified anchor fragments (step 1) are then docked into the 
binding site using the program SEED (Solvation Energy for Exhaustive Docking).
29
 The 
placement of fragments within the binding site is determined by matching either the 
direction of polar vectors between ligand and receptor atoms to form a hydrogen bond or 
the apolar vectors on the solvent accessible surface area of the ligand the receptor. The 
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Figure 4. Schematic depiction of fragment-based docking protocol implemented into 
CHARMMing. A- The main stages of the docking: decomposition by DAIM, fragment 
docking by SEED, and ligand placement by FFLD. B – Flow chart representing the 
sequence of the procedures of the protocol. CHARMM(ing) world grayed area represents 
the steps which include CHARMM compatible protein-ligand system. 
 
SEED score, used in fragment placement, accounts for the solvent effects by including 
terms for both receptor and fragment desolvation as well as a solvent screened receptor-
fragment electrostatic interaction term. 
A 
B 
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4.  The docked fragments are reconnected into the original ligand while undergoing 
refinement using the FFLD (Fragment-based Flexible Ligand Docking) program.
30
 FFLD 
uses a genetic algorithm that generates and evaluates populations of conformations and 
positions them within the binding site, as guided by fragment anchor locations. The 
fitness of a placed con- formation is evaluated using a scoring function that is aimed at 
approximating the steric effects as well as hydrogen bonding contributions of the protein-
ligand interactions. This function includes intra-ligand and protein-ligand van der Waals 
interaction terms as well as polar contributions based on the number of hydrogen bonds 
and unfavorable donor-donor and acceptor-acceptor interactions. 
5.  Poses generated by FFLD that are within a user defined energy cutoff (10 
kcal/mol by default) are then clustered using a leader clustering algorithm implemented 
in the program FLEA (FFLD Leader Clustering).
31
 
6.  Following the clustering, the protein-ligand complex is converted to native 
CHARMM format and saved. Using these files, in addition to the CHARMM protein and 
generalized force fields (i.e., CHARMM36 and CGenFF), protein structure (psf) and 
coordinate (crd) files are generated. Each ligand then undergoes one thousand steps of 
minimization using the adopted basis Newton-Raphson (ABNR) algorithm while keeping 
protein atoms fixed. The “minimized” protein-ligand complexes are then scored using 
SEED and FFLD in their “evaluation only” mode, producing their own estimation of 
electrostatic, van der Waals, and total energy contributions for each pose. The final 
ranking of the docked poses is performed using a consensus approach. For this, energies 
(i.e., interaction energy from CHARMM and total energies from SEED and FFLD) are 
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used to create three lists in which individual poses are sorted and ranked. The final rank 
of each pose is then set to  
 
Job Submission and Monitoring 
When a docking job is launched, the based queuing system TORQUE51 accepts the job 
as a wrapper shell script that controls the entire docking procedure. Using the interface, a job can 
be monitored in real-time as it progresses and generates final poses for each docked compound. 
Basic job statistics such as submission time and job status can be monitored along with the 
output file reflecting the job progression (Figure 5). In addition, important files associated with 
job progress and results (e.g., final docked ligand poses, job output, etc.) can be downloaded to a 
local disk. Protein, ligands, compounds in the library, and final docked poses can all be 
visualized directly in CHARMMing. The 3D structure of each of the above elements can be 
rendered with the JSmol
38
 or GLmol
39
 visualization tools. Structures can be visualized using a 
variety of representations to highlight important structural features or interactions of the 
molecules and their complexes. 
A walk-through outlining the entire process of performing a self-dock on a sample 
system is included in the tutorial covering basic CHARMM and CHARMMing functionality at 
www.charmmtutorial.org. Additionally a docking lesson that guides a user through the self-
docking procedure has been added to the lessons section of the CHARMMing website.  
 
Performance and Local Execution 
 Currently, all docking jobs executed via the Web interface are carried out sequentially. 
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Figure 5. The “Job Details” page. This page provides general job information as well as the list 
of docked poses and their respective scores. The docked poses can be visualized in 3D within the 
binding pocket of the protein using the embedded visualization application. An archive of the job 
directory can also be downloaded from this page for execution on local resources. 
 
However, after the initial setup of the docking job, all necessary files are available for download 
and execution on local computational resources. To improve performance of this procedure, we 
have developed a protocol that can be carried out in parallel as outlined in Figure 6. This is 
achieved by spawning a new execution branch for each of the most time consuming steps in the 
protocol via a user-modifiable job queuing command. For example, each fragment of each 
molecule is docked (step 3, vide supra) as a separate submitted job. Once all of a molecule’s 
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anchor fragments are docked, the placement of a ligand within the binding site by FFLD is also 
spawned as a series of separate jobs. Furthermore, to increase sampling by FFLD, and improve 
performance, the protocol performs multiple docking iterations per ligand, again each as a 
separate job. Thus, instead of one docking job that attempts to sequentially sample a large 
conformational space per ligand, multiple shorter iterations with different random seeds are run 
in parallel, taking less real time and still sufficiently sampling ligand conformational space. The 
number of iterations per ligand as well as the amount of energy evaluations per iteration are all 
user modifiable parameters.  
In order to execute a job on local resources the following programs need to be 
downloaded and installed: VMD,
40
 DAIM, SEED, FFLD, FLEA, MATCH, and CHARMM. 
Except for CHARMM, all of these programs are free for academic use. VMD can be 
downloaded from the University of Illinois at Urbana-Champaign’s Theoretical and 
Computational Biophysics group www.ks.uiuc.edu/Research/vmd). DAIM, SEED, FFLD, and 
FLEA can be obtained from the University of Zurich’s Computational Structural Biology lab 
(www.biochem-caflisch uzh.ch/download). Further, a more general description of the installation 
process is included as part of the CHARMM tutorial and can be found at the following address: 
www.charmmtutorial.org/index.php/Installation_of_CHARMMing.  
Once the job directory is downloaded and the software is installed on local resources, the 
provided settings file should be used to specify the location of program executables. In addition, 
job details (e.g., protein file name, number of docking iterations, clustering energy cutoff, etc.) 
can be modified via the settings file. This file is also where PBS/TORQUE commands can be 
modified for local resources. Because there is no limit to the number of possible parallel 
processes spawned, the protocol checks for available resources and will wait for current 
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Figure 6. Parallelization of the docking protocol. The parallelization is achieved by spawning 
new job execution threads at both the fragment docking (i.e., one per fragment) and ligand 
placement (i.e., one per iteration per ligand) steps. Clustering and scoring threads are also 
spawned for each docked ligand. 
 
 processes to complete if the queue is full. The protocol will automatically take advantage of all 
available resources to speed up job completion while at the same time adhering to the local 
queuing system policies. 
 
Results and Discussion 
To assess the performance of the docking protocol a diversity set was constructed from 
the publicly available CCDC/Astex test set,
41
 containing high resolution x-ray complexes, and an 
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augmented version of that set, which has been used to compare the performance of a number of 
docking programs.
42
 Our final set contained 24 protein - ligand complexes with x-ray resolutions 
ranging from 1.50Å – 2.30Å. In particular, we selected complexes where the ligand could be 
decomposed into three fragments (i.e., at least three rotatable bonds) using the default settings of  
DAIM; as the ultimate goal was to evaluate the implementation of the decomposition based 
approach. 
Self-dock validation involved removing the co-crystallized ligand from the complex, self-
docking it via the fragment-based protocol, and comparing the docked pose to that of the original 
crystal structure. Each complex was processed using CHARMMing’s “Submit Structure” section 
that downloads the structure based on the PDB code, adds hydrogen atoms, and prepares the 
structure for modeling using CHARMM. Further, each system containing the protein, solvent 
and ligand molecules was briefly minimized for 100 steps using the Steepest Descent method 
followed by 1000 steps of ABNR using CHARMMing’s “Calculations” module. Using the 
“Ligand Upload” section of CHARMMing’s docking module the previously downloaded ligand 
was processed. The docking calculation for each minimized system was set up by selecting a 
native ligand to define a binding pocket and user-uploaded ligand for docking, all from the 
“Submit Docking Job” page of the docking module. The progress of each job was monitored 
using the job monitoring section of the docking module. To assess the performance of the 
dockings, root-mean-square deviation (RMSD) between the heavy atoms of the docked poses 
and the crystal structures was calculated using VMD. 
To compare the docking protocol’s performance, a commercially available docking 
package was also used. Self-dockings were performed using Schrödinger’s Glide22–24,43 Standard 
Precision (SP) docking protocol. Glide’s SP protocol attempts to dock multiple conformations of 
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a ligand into a receptor grid, subsequently calculating the effective ligand-receptor interactions 
using a proprietary scoring function. Conformational sampling of the ligand is achieved via 
varying torsion angles around rotatable bonds. Prior to docking, each target was prepared using 
Maestro’s44 Protein Preparation Wizard.45–49 The preparation included removal of solvent 
molecules, addition of hydrogens, and brief minimization. As Glide is also a grid based docking 
protocol, the grids, similarly to CHARMMing’s procedure, were built using the co-crystal ligand 
to define the binding region. The native ligand was removed and self-docked using default 
parameters of the SP docking protocol. The poses with the best docking scores were used to 
calculate their respective RMSD from the crystal structure using VMD. 
Table 1 reports the RMSD of poses generated by CHARMMing’s fragment-based 
docking protocol and Glide SP docking (w.r.t. crystal structure). Results reported from 
CHARMMing’s fragment-based docking protocol correspond to the pose closest to the crystal 
structure. This set yields a 71% success rate using RMSD <2.0 Å as the metric; this criteria is 
commonly employed for evaluating the performance of docking algorithms.
42,50–52
 This clearly 
shows that the protocol can successfully recover the crystal pose in the majority of the cases. 
Optimization of the consensus scoring function is planned as part of the future improvements to 
the protocol. Nevertheless, virtual screening is known to suffer from high false-positives rate, 
which does not diminish its value in drug discovery as the unfit compounds are screened out 
during the experimental stages of the discovery campaigns.
53
 Regardless, we are encouraged by 
the success of fragment-based docking, which shows approximately the same performance as 
widely used docking programs, i.e., within the range 40% – 90%.42,50–52  
The fragment-based approach that was implemented into CHARMMing yields a 
substantial amount of information about the characteristics of each docked pose. At each 
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Table 1. RMSDs of the docking poses generated by CHARMMing’s fragment-based docking 
protocol and Glide SP and the success rates (defined by the percentage of the ligands whose 
reported RMSD is below 2.0Å). “Best RMSD” refers to the pose closest to the crystal structure. 
Glide SP RMSD is of the top scoring pose of Glide’s standard precision docking. 
 
 
 
step, from decomposition to minimization of docked poses, users have the ability to closely 
analyze results. The binding modes of each individual fragment can be inspected and a number 
of modifiable parameters, such as decomposition criteria, can be used to optimize the protocol. 
Moreover, information gained from docking a fragment library into a particular target can be 
used to mine large libraries for compounds containing those fragments that form the most 
favorable interactions with the target.
54–56
 
There are potentially a number of improvements that can be made to improve the 
performance and usability of CHARMMing’s docking protocol. The most obvious limitation is 
the current requirement of three fragments to be used as anchors. As can be seen by the number 
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of ligands eliminated from the original benchmarking set, this limits the applicability of this 
protocol in its current form to medium to large sized molecules with a sufficient number of 
rotatable bonds. Although partially this problem can be alleviated by decreasing the fragment 
richness threshold at the decomposition step, this will only increase the “eligibility” rate of 
molecules by a small margin. Alternatively, when docking these small and/or rigid molecules is 
desired, the decomposition step could be omitted at which point the molecules would undergo  
docking only by SEED. This however will require prior conformation sampling step as SEED 
currently does not sample the internal conformation of docked fragments. The conformational 
sampling of the fragments is an obvious improvement to the docking protocol even in its current 
state. This addition will help ensure that larger fragments sample their orientations within the 
binding site while varying their internal geometry, thus ensuring greater enrichment of anchor 
positions for the final ligand placement. Efforts to incorporate these functionality improvements 
are currently underway. 
 
Conclusions 
This work has described the implementation of a fragment-based docking protocol into 
the CHARMMing Web interface. The protocol allows users to perform docking and virtual 
screening calculations online as well as generates self-contained scripts to execute these in 
parallel on local HPC resources. The performance of the docking protocol was evaluated by 
carrying out the series of self-dockings and comparing the results against a top commercial 
docking package. The fragment-based docking protocol yielded results comparable to both the 
commercial package used herein and a wide variety of additional docking software. Specifically, 
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the rate of recovering the correct x-ray pose with CHARMMing’s protocol was 71%, well within 
the 40% – 90% range that numerous benchmarking studies have reported. 
While the scoring function that CHARMMing uses to rank poses can still be improved, 
the tool lays substantial ground work for allowing academic labs to set up and perform molecular 
docking and virtual screening studies. It is important to note that the protocol is able to create 
CHARMM formatted protein-ligand systems giving users the ability to access the wide range of 
functionality that exists in CHARMM. For example, docked poses can easily be refined with MD 
simulations and pre-docked proteins can be coupled with simulations or normal mode analysis to 
proceed via an ensemble docking approach. These, in addition to other improvements are 
currently being developed. 
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CHAPTER THREE: 
DEVELOPMENT AND APPLICATION OF THE VIRTUAL TARGET SCREENING 
PROTOCOL 
Development of the Virtual Target Screening Server  
Methodology Background 
 Active development and, in large part, acceptance of docking algorithms and software in 
recent years has allowed the concept of virtual screening gain the status of a widely used tool 
during early stages of drug discovery.
1–5
 Virtual screening (VS) involves docking of a set of 
small molecules into a binding site of a target of interest represented by a computer model. 
Depending on the availability of computational resources and the nature of the docking 
algorithm used, rather large (millions of compounds) libraries of molecules can be docked in 
such manner. VS represents a quick and less thorough and less expensive sweep of the chemistry 
space than most other computational or experimental techniques. This allows researchers to start 
with a broader representation of the chemistry space and narrow down the list of potential drug 
candidates committing additional computational and experimental resources to a more focused 
set of compounds further down the discovery “funnel”.1–5 
 The idea of virtual target screening (VTS) is based on the same molecular docking 
principles, however is applied in reverse, hence its other common names - inverse docking or 
virtual counter - screening. VTS involves docking of a single molecule of interest (MOI) into a 
set or a library of proteins. Thus, VTS’s applicability in the context of a discovery project 
becomes rather different from that of the conventional VS as VTS is applied at later stages of 
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drug discovery. The MOI, as its name suggests, is usually a chemical substance of particular 
interest. MOI may be a hit that resulted from a VS campaign, or most commonly it is a lead or a 
drug candidate. In the latter case VTS can help gain insight into promiscuity of the lead 
compound or its selectivity towards a particular target. VTS, due to its very nature, is an 
approach to take when drug repurposing or repositioning is sought. In this case the MOI is often 
an already existing approved drug. However MOI can also be a drug candidate that failed at a 
later stage of development for a particular indication and an alternative mode of action is being 
probed. 
 VTS is an approach that is beneficial at multiple stages of drug discovery and has the 
potential to save substantial costs and efforts by identifying problematic compounds at earlier 
stages of the discovery. It can also help find new directions in the development of a 
pharmaceutical agent, gain important insight into the relationships between different ligand and 
protein families and help identify biological targets of known chemical substances. The 
remainder of this chapter focuses on the implementation of the VTS server on a private network 
of H. Lee Moffitt Cancer Center using CHARMMing open source framework as its base. In 
addition, two examples of applicability of VTS protocol in the context of drug discovery are 
presented. First example focuses on identifying potential targets for natural products, while the 
second case describes the application of VTS to search for biomolecular targets of vitamin E δ-
tocotrienol. 
 
VTS Protocol 
 There exist a number of systems based on the concept of virtual target screening.
6–9
 
Although the main goal remains essentially the same, different approaches have been taken to 
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arrive at it. Some implementations compare MOI to known actives, some put emphasis on the 
comparison of binding sites. While these approaches are useful and even successful each in their 
own way, the problems still remain. Lack of known actives with sufficient affinities for a 
particular target, insufficient amount of structural information to thoroughly define special 
descriptors of binding sites all present challenges.  
 VTS protocol implemented at the Moffitt Cancer Center uses a procedure developed by 
Santiago et.al.
10
 The procedure includes a calibration step for each protein in the database. The 
calibration is intended to establish standards that an MOI should meet in order to be interpreted 
as a “hit” according to the protocol. The calibration involves docking of the National Cancer 
Institute (NCI) Diversity Set I
2
 consisting of structures of 1990 drug-like compounds and 
recording the average docking scores of top 20 and top 200 scoring compounds as well as overall 
average and Boltzmann weighted average. The calibration is performed on each of the 1,567 
protein structures in the VTS database. Upon docking of MOI, the docking score of the MOI is 
compared to the top 20 average for that protein and if MOI scores better it is considered as “hit”. 
If a screen results in a small number of hits, the criteria can be expanded to the top 200 average. 
 
VTS Web-based interface 
 To facilitate the application of the VTS protocol, a web-based interface that provides a 
user friendly, quick and automated tool for docking MOIs into collections of user-defined 
proteins was developed. The framework for the online VTS interface is based on the open 
CHARMMing package. Publicly available installation of CHARMMing framework was used to 
deploy it on a server that was a part the private network of Moffitt Cancer Center. The 
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installation has provided basic out of the box components that included database storage engine, 
user management system, batch job scheduling infrastructure and a user interface with basic 
structure processing and job submission and monitoring functionality. The graphical Virtual 
Target Screening (gVTS) system includes tools necessary to set up and initiate VTS experiments. 
Functionality implemented in the context of this project includes the following: 
 Maintain a library of protein grids for docking of small molecules. 
o User-prepared grids, based on the proteins of interest can be uploaded and stored 
in the internal database. 
o Ability to create custom grid sets that can represent structures specific to a given 
VTS experiment. 
 Maintain database of MOIs. 
o User can submit MOIs either by uploading the Cartesian coordinates or by 
drawing a molecule via a 2D chemical drawing interface, JChemPaint 
(jchempaint.sourceforge.net), which is included in gVTS (Figure 7). 
o All submitted MOIs are atom-typed and energy minimized with MacroModel.11 
 Initiate VTS runs and analyze results 
o VTS jobs can be set up with any number of MOIs against either the entire library 
of proteins or a custom created subset. 
o Job runtime estimation algorithm predicts an approximate execution time based 
on the number of MOIs, rotatable bonds per MOI, and number of screened 
proteins. 
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 Job scheduling and queuing system provided by the CHARMMing interface allows for 
submission of multiple jobs and can be interfaced to popular queuing systems such as 
Torque, PBS, and sun grid engine (with slight modifications). 
 Complete, up to the second, information on any job currently running or run in the past is 
available and includes but is not limited to the status of the job, information about any 
resulting hits, structures being screened/hit, log, and output files. In addition, the user is 
able to visualize the docking pose of any MOI in a protein hit (Figure 8). 
 User authentication system 
o To ensure privacy of the data, the Django/CHARMMing based user 
authentication system in combination with database identifiers protects each 
user’s information such as MOIs, protein structures, jobs, etc. and allow access 
only by authorized persons. 
The interface has been developed using the underlying CHARMMing infrastructure at 
the time of the implementation using Python 2.6 programming language and the Django 0.96 
object framework. A MySQL 5.1.37 database is used to maintain system information and user 
generated data. Perl scripts provide the interface to the Schrodinger
12
 software suite. 
 
 Figure 7. Example use of the JChemPaint 
applet embedded into the gVTS. This 
particular example illustrates the user-
drawn structure of Staurosporine. 
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Figure 8. Illustration of VTS screen results page. The results of the screening of Staurosporine 
against a set of kinases. 
  
Application of VTS to Identify Protein Targets of Natural Products in Drug Discovery 
Natural Products and VTS 
 Natural products have historically been of interest to the drug discovery community. 
However, despite the availability of a wide range of drug discovery techniques and the growing 
number of synthetic compound libraries the number of newly discovered drugs has dropped in 
recent years.  This trend has largely been the impetus for the renewed interest in natural products 
in drug discovery
13–19
. Moreover recent advances in extraction, purification and structure 
determination techniques along with improved screening methods such as miniaturized high-
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throughput phenotypic assays have made it less challenging for natural products to be 
interrogated with respect to their potential as therapeutic.
20–22
 
 The initiative to screen a collection of natural products described in this work consisted 
of two separate subtasks. Both tasks essentially amounted to a combination of conventional 
virtual screening and virtual target screening in a sense that the collections of natural product 
compounds were screened against a collection of proteins in the VTS database. One task 
involved screening of a publically available set of natural products from the Developmental 
Therapeutics Program (DTP) of the National Cancer Institute (NCI). Another task was screening 
of non-public set of natural products from the Center for Drug Discovery (CDD) and Innovation 
at the University of South Florida (USF) in Tampa. The NCI set contains publicly accessible 
compounds and it includes molecules which have been mentioned in various published studies 
and have experimental data available to public. This means that in principle the results of VTS 
screen can be compared and possibly correlated with the available experimental data reported 
elsewhere. In contrast to the NCI set, CDDI set consists largely of molecules with little or no 
publicly available data. This means that it may be impossible to correlate the results of the VTS 
screen with any experimental data. However even without experimental consensus VTS can be 
used to gauge the potential of a natural product as to its likelihood of binding to target proteins. 
 
Materials and Methods 
Virtual Compound Libraries 
The NCI Diversity Set I, consisting of 1,990 virtual compounds, was obtained from the 
National Cancer Institute’s (NCI) Developmental Therapeutics Program (DTP) and used as 
described previously for our VTS system
5,23
. 
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The NCI natural Product Set II includes 120 compounds
2
. Due to cost and time 
considerations, we selected 67 compounds that ranged from 314 to 692 Daltons in a loose 
application of “Lipinski’s rule of 5”. These compounds were screened in VTS. The NCI DTP 
website also provides links to published experimental data on the compounds in their virtual 
libraries
24. This allows for comparison and validation of VTS “hits” against known 
experimentally-determined interactions of the compounds when the data is available.  
The CDDI library provided to us contained virtual structures for 160 natural product 
compounds, many originating from marine sources
25
. These are from the larger collections at the 
CDDI, which include over 2,500 extracts and 950 characterized bioactive compounds. Again, 
due to cost and time consideration, we selected 87 of these compounds for VTS testing with a 
range of 350–675 Daltons. 
 
Ligand Preparation 
Prior to screening all compounds were prepared using the LigPrep utility in Schrodinger's 
Maestro software.
26,27
 LigPrep generates 3D structures of all tautomers, ionic states and 
stereoisomers of input compounds. In the case of NCI compounds the structure files have 
indicated chiralities of some stereo centers. Therefore, when preparing the ligands, only the 
unspecified centers were allowed to sample different chiralities. For CDDI compounds however, 
to reduce computational time and the amount of isomers, all the chiralities were inferred from the 
3D structure. As a result, LigPrep generated a total of 1133 structures from the 67 original NCI 
compounds and, because no chiralities were varied in the case of CDDI set, a total of only 103 
structures resulted from LigPrep for the 87 original CDDI compounds. 
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Virtual Target Screening 
We selected primarily human proteins as the targets for this VTS exercise, which yielded 
1,059 target grids representing 1,011 unique crystal structures. For this exercise with a large 
number of MOIs to process in VTS, we estimated there would be over one million docking and 
scoring calculations. Therefore, the compounds were divided into 25 separate files, each 
containing subsets of 30–60 structures. This was done to effectively parallelize the VTS 
calculations. Each of these subsets was then uploaded through the VTS web interface’s MOI 
upload section. A screening job was then launched from the VTS web interface for each of the 
25 subsets to be screened against all 1,059 target grids. On average each job took approximately 
30 hours to complete. When analyzing the results of the screening jobs, a compound-protein was 
deemed to be a “hit” if the score outperformed the average score for the top 20 NCI diversity set 
compounds for that protein structure. The “hits” were compared against the literature for 
consistency with published experimental data. The PubChem database was used to look-up 
experimental activities for the compounds that hit one or more targets.
28,29
 
 
Hardware 
VTS was originally developed and run on a Dell Precision 490 workstation running 
Fedora 8 Linux with dual Xeon 3.06 GHz processors, 4 GB RAM and a 250 GB hard drive. This 
was sufficient when running one or a few MOIs but, for the larger sets of MOIs for the 67 NCI 
natural products and the 87 CDDI natural products, we incorporated execution on a local cluster 
we have developed in the Virtual Screening & Molecular Modeling Core at H. Lee Moffitt 
Cancer Center & Research Institute. This cluster is comprised of 6 racks each containing 8 Intel-
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based dual core desktop computers connected via a NETGEAR Pro Sage 16 router (model 
GS716T). 
 
Graphics and Modeling 
Visualization of docked MOIs in protein targets was performed with Schrödinger’s 
Maestro, a graphical user interface that allows modeling and facilitates use of many of 
Schrödinger’s applications with the models, such as MacroModel and Glide5,11,30. Refined 
depictions used for publication figures were developed using Schrödinger’s PyMol.31 
 
Results 
VTS on NCI Natural Products 
Upon compilation of the results of all the jobs, a total of 13,278 hits were identified for 
the NCI Natural Products Set II compounds tested. For 4 of the screened NCI molecules VTS 
identified a total of 16 targets against which screened compounds were found active in one or 
more experimental assays (Table 2). The most “active” MOI Daunorubicin (Figure 9) hit a total 
of 6 unique proteins. The most interesting of those hits can be considered the Lck tyrosine kinase 
protein. Daunorubicin has hit 5 different structures that represent this protein. Moreover in at 
least two reported assays Daunorubicin had indeed shown activity against this particular target. It 
may be speculated that a compound hitting multiple structures of the same protein may indicate 
likely activity against that protein. In addition, results of the NCI natural products screen show 
preference of some compounds towards one or more protein families as can be seen in the case 
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of Wortmannin and a kinase family (Table 2). It should be noted however that kinases are 
disproportionally well represented (25%) in our protein database due to their importance in 
cancer. Still an insight like this can be used to gauge the potential for more specific targeting as 
well as possible promiscuity of an MOI. 
 
Table 2. Top NCI natural products screen hits. Compounds with known activity against the 
targets that have been identified as hits in the VTS screen. Column 1 contains the NSC 
number of the compound, column 2 contains the common name of the compound, column 
3 contains 2D sketch of the compound, column 4 contains the name of the protein targeted 
by the compound, column 5 shows the number of unique structures representing the target 
identified as a hit for the given MOI, column 6 is the number of assays that have reported 
activity of the MOI against this target. 
 
 
 
 
NSC Compound 
Name 
Structure Target # of unique 
structures 
identified by 
VTS* 
# of assays 
reporting 
activity 
82151 Daunorubicin 
  
Lck tyrosine kinase 
Estrogen Receptor 
Alpha 
Epidermal Growth 
Factor Receptor 
Thyroid hormone 
receptor 
Mitogen Activated 
Protein Kinase 14 
Fyn tyrosine kinase 
5(11) 
 
 
2(6) 
 
 
3(5) 
 
1(6) 
 
 
1(39) 
 
1(3) 
2  
 
 
8  
 
 
1  
 
4  
 
 
1  
 
1  
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Table 2 (Continued) 
* - Number in brackets denotes the total number of structures in VTS database. 
** - VTS screening included and hit the human version of the protein while the experimental 
data is on mouse. 
*** - VTS screening included and hit the human version of the protein while the experimental 
data is on a structurally similar Plasmodium falciparum. 
5159 
Chartreusin 
  
Urokinase-type plasminogen 
activator** 
Heat Shock Protein HSP 90-alpha*** 
 
Cyclin-Dependent Kinase 5 
2(35) 
 
1(13) 
 
1(2) 
1  
 
1  
 
1  
221019 
 
Wortmannin 
  
Cyclin-Dependent Kinase 2 
 
Serine/threonine kinase PIM1 
 
Src tyrosine kinase 
 
Lck tyrosine kinase 
Cyclin-Dependent Kinase 5 
3-phosphoinositide-dependent protein 
kinase 1 
6(105) 
 
 
2(17) 
 
2(36) 
 
1(11) 
1(2) 
 
1(9) 
1  
 
 
1  
 
1  
 
2  
1  
 
1  
345647 Chaetochromin 
  
Glutathione-S-transferase Omega 1 
 
 
1(3) 
 
 
 
 
 
2  
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Figure 9. Daunorubicin docked into Lck. Daunorubicin’s docked pose according to the VTS 
docking procedure. Inset shows the local hydrogen bond interactions in yellow dashed lines as 
well as the residues with which these interactions are formed in stick representation. The Lck 
structure was 1QPJ.pdb.
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VTS on CDDI Natural Products 
The screening of CDDI compounds against our database has also yielded interesting 
results. Although assay information is not as readily available for these compounds, the results of 
the VTS can still show interesting trends and insights valuable for drug discovery. Table 3 shows 
the top 40 hits where the MOI has outperformed the top performers of the calibration set by the 
largest margin, thus making these compounds more likely to be tighter binders to the indicated 
targets. It can be seen that there are a number of molecules, as identified by their unique 
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molecular weight that hit several targets, as is especially the case with compounds 374, 587 and 
629. Once again, this may be an early indicator of potentially promiscuous compounds. At the 
other end of the spectrum are compounds such as 287, 368 (Figure 10), 437, 530 and 674. These 
compounds only hit one target. Especially interesting are those compounds with lower molecular 
weight as it is easier for a larger compound to score high based on the increased number of 
favorable interactions it can form with the protein. If a smaller sized yet still a drug-like 
compound such as 368 significantly outperforms a calibration set for a single particular target, it 
may be worthy of a further inquiry as a potential binder to that protein. 
Table 3. Top CDDI set hits. Top 40 hits based on the largest margin by which an MOI 
outperformed the top 20 calibration set average. First column contains the name of the 
target protein with co-crystallized ligand identifier in square brackets. Second column 
indicates the percentage by which a given MOI outscored the average docking score of the 
top 20 calibration set molecules for that target. Third column contains the rounded 
molecular weight of a docked MOI and serves as its identifier. The table is sorted by the 
molecular weight. 
Target 
Outperformed 
calibration by (%) 
Molecular Weight 
(compound ID) 
[R11]Coagulation factor x 28 287 
[L1G]HCK 28 368 
[NHB]Histone deacetylase 8 30 372 
[NHB]Histone deacetylase 8 24 372 
[NHB]Histone deacetylase 8 36 374 
[AO5]Methionine aminopeptidase 2 35 374 
[GIP]Protein (lactoylglutathione lyase) 35 374 
[NHB]Histone deacetylase 8 29 374 
[GIP]Protein (lactoylglutathione lyase) 30 374 
[AO2]Methionine aminopeptidase 2 23 374 
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Table 3 (Continued) 
[NHB]Histone deacetylase 8 26 437 
[NHB]Histone deacetylase 8 23 530 
[HYF]Orphan nuclear receptor pxr 35 587 
[HYF]Orphan nuclear receptor pxr 33 587 
[QPP]CAMK1D 32 587 
[SWF]CYP2C9 26 587 
[DEO]Macrophage metalloelastase 20 587 
[XLD]Coagulation factor x heavy chain 30 587 
[RAP]Fkbp25 36 587 
[SDK]Cathepsin K 30 587 
[POS]Cathepsin K 30 587 
[INA]Cathepsin K 29 587 
[POS]Cathepsin K 28 587 
[BOG]p38-alpha(MAPK14) 25 587 
[2CA]Cathepsin k 27 587 
[FMM]Epidermal growth factor receptor 23 625 
[L1G]HCK 39 629 
[471]Peroxisome proliferator activated 
receptor 
42 629 
[U66]Protein farnesyltransferase alpha 
subunit 
31 629 
[CIU]Epoxide hydrolase 2- cytoplasmic 29 629 
[POS]Cathepsin K 33 629 
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Table 3 (Continued) 
[SDK]Cathepsin K 31 629 
[HYF]Orphan nuclear receptor pxr 25 629 
[155]Urokinase-type plasminogen activator 27 629 
[SAH]Histamine MeXferase (Ile105Var) 22 629 
[AIJ]Estrogen receptor 21 629 
[BNE]Protein farnesyltransferase alpha 
subunit 
21 629 
[BOG]p38-alpha(MAPK14) 23 629 
[LA1]Integrin alpha-L 31 663 
[LA1]Integrin alpha-L 19 674 
 
Discussion 
We have used 67 compounds from the NCI Natural Products Set II to test our VTS 
system for its ability to virtually identify potential protein targets, i.e. “hits” that can be 
compared to published data for those compounds. We have also used 87 compounds from 
the CDDI natural products to assess their potential interactions with protein targets when 
they were screened through VTS. The work has also brought to light improvements that 
can be made to the current VTS system to make it more applicable to our new areas of 
application in drug discovery and development: infectious diseases and natural products, 
particularly marine natural products. There is an unmet need for large-scale drug discovery 
efforts with marine natural products.
34,35
 There is also opportunity for these large-scale  
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Figure 10. 368 docked into HCK. 368’s docked pose according to the VTS docking 
procedure. Inset shows the local hydrogen bond interactions in yellow dashed lines as well 
as the residues with which these interactions are formed in stick representation. The HCK 
structure was 2COI.pdb.
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efforts with marine natural products and natural products in general to be used more in academic 
settings, such as the CDDI.
36
 Drug discovery efforts with marine natural products have been 
successful with 13 products in clinical trials in 2010 and so these efforts should be expanded to 
take advantage of new natural products from new marine sources.
37
 In order to scale-up these 
efforts and make them more productive, particularly as natural product libraries grow, innovation 
is needed.
38
 We believe that VTS is an innovative, cost-effective approach to address the needs 
for rapid identification and appraisal of natural products. Besides our previous paper
23
 in which 
we compared our VTS results against experimental data focusing on kinases, there are other 
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recent reports in which other groups have compared results from computational drug repurposing 
applications against experimental data demonstrating the usefulness of the tools.
39,40
 
This exercise demonstrates that VTS can identify potential promiscuity of natural product 
compounds that may deter further development of an MOI if the promiscuity is experimentally 
confirmed for some of the “hit” proteins. VTS can also give ideas of other targets that may not 
have been considered previously for the MOI. However, since our VTS protein collection is 
limited, we cannot yet consider the VTS runs as comprehensive searches. There may be more 
proteins that would arise as “hits” for these compounds if those proteins had been included. 
Other systems are now available online for screening compounds against collections of protein 
structures, such as HitPick,
41
 ChemMapper,
42
 and Mantra.
43
 A comparison of VTS and other 
target finding applications was beyond the scope of this study since our purpose was to analyze 
VTS with regards to natural products and infectious disease targets. However, we did test two of 
the top scoring compounds (wortmannin and daunorubicin) from the NCI Natural Products II 
and got similar hits of kinase proteins as were found by HitPick. A thorough study comparing the 
various target finding applications is certainly warranted now that more applications are 
published but it should be comprehensive with regards to ligands (small synthetic molecules and 
natural products). We believe the VTS approach has benefits in that it can be used towards 
different sites on a protein, such as allosteric sites, for which there may not be any previously 
known ligands. We can use Schrödinger’s SiteMap as a means of identifying potential binding 
sites [54,55].
44,45
 The drug-like molecules of the NCI Diversity set can quickly calibrate new 
sites even when there is no previous data. Many other applications are dependent on previously 
known ligands for specific binding sites in order to make their assessment of an MOI’s 
interactions.  
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VTS also can be used to compare an MOI against known inhibitors of VTS “hit” proteins 
and to compare the MOI against its own analogs to test focusing by functional groups as rational 
design is applied to the MOI to generate improved analogs. Some of the analogs may show more 
specificity to the intended target and generate fewer VTS “hits”, suggesting that the analog is an 
improvement over the original MOI. With regards to a known inhibitor, if the MOI shows more 
specificity (fewer VTS “hits”) than the inhibitor, this can increase interest for the MOI. 
The main purpose of VTS is to identify new targets for an MOI, whether they are new 
targets for repurposing or targets that may indicate possible adverse interactions. For VTS to be 
effective towards this purpose, we need to increase our collection of proteins. Since VTS was 
originally developed for supporting oncological drug discovery projects, the emphasis was for 
inclusion of primarily human proteins. For testing compounds in VTS for infectious disease 
projects, we need a great increase in protein structures from viruses, bacteria and other 
microorganism that are relevant to those diseases. We need to grow the VTS protein collection as 
much as possible using as many structures from the Protein Data Bank, but we still want to focus 
on those structures that have high resolution (~2.0 Å or less) and primarily wild-type proteins. 
We realize now that, even towards oncological drug discovery, proteins from microorganisms 
are important in VTS since often the beneficial microbes in the patient’s gut microbiota can be 
adversely affected by drug therapy. And of course there need to be more proteins represented for 
the problematic microorganisms in infectious diseases. 
We intend also to include more proteins involved in protein-protein interactions. The 
target sites may be more difficult to isolate for Glide grids and so multiple copies of the protein 
structure with grids at different sites could be used. We can use Schrödinger’s SiteMap utility to 
identify potential binding sites as part of the protein preparation and center the Glide grids on 
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those sites.
44
 Disruptors of protein-protein interactions can conceivably be larger than typical 
small molecule substrates of enzyme active sites and so we would want to expand VTS to deal 
with larger MOIs. This would require an additional approach to calibrating the prepared proteins. 
We can envision using a designed virtual di-, tri- or tetra-peptide or peptidomimetic library for 
an additional set of averages to use in calibration and VTS analysis. These averages of larger 
molecules would be of use for larger MOIs, which can occur with natural products. Another 
possible improvement is to incorporate into VTS an assessment of ligand binding efficiencies. 
We can improve overall interpretation of VTS dockings by taking into account the number of 
non-hydrogen atoms to avoid inflation of the scores for larger ligands. The basic approach would 
be to divide the GScore by the number of non-hydrogen atoms. In addition, approaches being 
developed to assess drug-likeness need to be incorporated, such as the QED approach.
46
 Another 
issue to address in improving VTS is the quality of the prepared proteins. MacroModel has been 
used in VS and VTS for achieving a relaxed state, more in vivo-like, for the protein compared to 
the original crystal structure. However, we might think of this as local relaxation of protein 
domains, whereas a thorough molecular dynamics (MD) relaxation of the protein, in which it is 
put in a virtual environment that simulates the individual water molecules and ions, can relax the 
protein to a global energy minimum in solution that may be even more pertinent to creating the 
protein in a realistic state for screening. In the last few years MD applications, such as 
Schrödinger’s Desmond, have become available so that we can now implement MD into our 
protein preparation steps.
47
 This implies that we should reprocess our existing protein collection 
with MD as well as apply MD to new proteins. MD requires more powerfully processing power 
and memory, which we can now access with clusters making these improvements feasible. 
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VTS and VS are developed primarily towards screening for non-covalent interactions of 
ligands and proteins. High-throughput virtual screening of potential covalent inhibitors has not 
been developed to our knowledge. This would be an interesting addition but does present many 
difficulties, even to develop a limited application. It would require a list of potential reactant 
groups, identifying key reactive residues in a protein that could be in play, and an algorithm to 
compare distances, charges and intermediates. It would seem to preclude the actions of cofactors 
and other agents. So covalent screening, at least with current tools, would be too challenging. 
However, it is interesting to contemplate such tools and their potential benefits in drug discovery. 
 
Conclusion 
This work has shown the potential for VTS with natural products to identify targets that 
may represent new purposes for the MOI, possible promiscuity of an MOI, or possible adverse 
interactions that warrant further investigation. Our VTS system can serve these purposes but we 
have used this current work to identify issues to improve in order to maximize the use and 
benefits of VTS for infectious disease drug discovery projects, particularly with newly acquired 
marine natural products. 
 
Using molecular modeling, chemo- and bioinformatics to search for biomolecular targets of 
vitamin E δ-tocotrienol 
Introduction 
 Vitamins, a subclass of natural products, have long been thought to play an important role 
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in physiology of living organisms. Many essential processes in the human body rely on the 
availability of vitamins. At the same time, while few dispute the importance of vitamins, in many 
cases their precise mode of action that manifests into health benefits remains elusive. This is not 
surprising however, as understanding the underpinnings of a biological effect of a small 
molecule requires the knowledge of its biomolecular target. Zeroing in on the precise mode of 
action of many vitamins is made more complicated by the fact that many come in various forms 
and induce a range of physiological responses. Vitamin E (VE) is good example of such 
complexity. VE is an essential lipid-soluble vitamin
 
and an important macronutrient that has long 
been thought to have strong antioxidant effects without causing major toxicity in humans.
48–50
  
Its primary activity has been attributed to its ability to reduce free radicals to prevent lipid 
peroxidation of polyunsaturated fatty acids.
51
 VE consist of 8 naturally occurring isomers, d-
alpha-, d-beta-, d-gamma-, and d-delta-tocopherols and d-alpha-, d-beta-, d-gamma-, and d-delta-
tocotrienols.
52
 Among the constituents of VE, tocopherols have initially received a great deal of 
attention from scientific community due to their potent antioxidant properties and their 
abundance in common food sources. Recently however the focus has been shifting towards 
tocotrienols which, although rare in nature, have exhibited a number of physiological effects that 
include neuroprotective, antioxidant, anticancer, cholesterol lowering and other therapeutic 
activities.
53–57
 The diversity and, at the same time, specificity of physiological responses to 
tocotrienols may mean that their modes of action differ from the broad antioxidant activity of 
tocopherols. A quick look at the structures of tocopherols and tocotrienols reveal three double 
bonds in the farnesyl isoprenoid tail of the tocotrienols making it a less flexible of the two 
classes of compounds (Figure 11). This additional restraint on the conformational freedom of 
tocotrienols however may be the reason for the more specific range of activities. The 
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significantly reduced number of allowable conformations of tocotrienols over tocopherols may 
result in the increased affinity of tocotrienols towards a specific group of binding partners. If this 
is true, tocotrienols' activity goes beyond that of a broad antioxidant and into the signaling realm. 
Studies of Vitamin E delta-tocotrienol (VEDT) have already proposed the notion that at least 
VEDT's anti-cancer activity may be attributed not to its antioxidant properties but rather to its 
involvement in the signaling pathways of cancer.
58–60
 Furthermore VEDT was proposed to act as 
a mediating substance in antiproliferative and apoptotic mechanisms in carcinogenic tumor 
cells.
52,56,58,61–64  
Present study attempts to gain insight into possible modes of action of the 
Vitamin E δ-tocotrienol (VEDT) by using molecular modeling, chemo- and bioinformatics to 
propose VEDT's likely binding partners. 
To complement experimental efforts directed at pinpointing molecular target(s) of VEDT 
this study takes advantage of in silico approaches to interrogate the protein space for potential 
targets. As the in silico target discovery gained prominence as viable tool in the at various stages 
of research campaigns, a number of methodologies have been developed to take advantage of 
computational efficiency and storage capabilities of computer systems to search for potential 
protein targets.
65–71
 
 In this study a number of different approaches were used to computationally probe for 
potential target proteins of VEDT. Moreover, the methods used in this study vary significantly in 
their approach yet aim to solve the same problem. This was done in part to decrease the effect of 
errors resulting from each individual tool. More importantly the results drawn from the 
consensus reached via the utilization of different approaches have shown to produce more 
reliable results.
72–75
 One method called Virtual Target Screening (VTS) is based on the explicit 
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Figure 11. Comparison of the structures of δ-tocopherol and δ-tocotrienol. The additional double 
bonds of δ-tocotrienol make it more conformationally constrained which can lead to its increase 
preference towards particular type of targets. 
 
modeling the intermolecular interactions between VEDT and its potential targets via a docking 
protocol designed specifically to search for targets of small drug- or natural product-like 
compounds.
10,76
 Other methods PharmMapper
77,78
 and PASS (Prediction of Activity Spectra of 
Substances)
79–81
 take a chemoinformatics approach to proposing potential target of a molecule of 
interest. Here the structure of VEDT and its pharmacophore is compared to a database of 
structures and pharmacophores of small molecules with known biomolecular targets. The target 
proteins are then proposed based on the structural similarities between database compounds and 
VEDT. Lastly binding site analysis tool ProBiS
82–85
 was used to mine the Protein Data Bank
86,87
 
for proteins containing binding pockets similar to those that are likely to accommodate VEDT. 
 
 
δ-tocopherol 
δ-tocotrienol 
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Methods 
VEDT Preparation.  
3D coordinates of VEDT and δ-tocopherol were downloaded from PubChem (citation) in 
an SDF (Structure Data File) format and were prepared using a LigPrep
27
 module of the suite of 
molecular modeling software Schrodinger
26
 with default settings corresponding to physiological 
pH.  
 
Virtual Target Screening.  
VTS, a web-based software deployed on a private computer network of the Moffitt 
Cancer Center
10,76
 was used as a molecular modeling component of this study. VTS was used to 
identify potential binding partners of VEDT by the means of molecular docking. The MOIs 
(VEDT and δ-tocopherol) were docked into each of the protein in the library. In addition to 
human protein structures which comprise the majority of the VTS library (~1000) structures 
from other organisms ranging from bacteria to mammals were also present and were included in 
VEDT screen for completeness. Once docked, MOIs’ docking performance as measured by their 
docking scores were compared to those of the calibration set compounds for each protein. A 
protein was considered a hit if MOI’s docking score was better than the average docking score of 
the top 200 calibration compounds docked into the protein.  
 
PharmMapper.  
PharmMapper uses pharmacophore mapping to identify potential targets for the MOI. Six 
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pharmacophore features including hydrophobic center, positively charged center, negatively 
charged center, hydrogen bond acceptor and donor vectors and aromatic plane of an ensemble of 
the MOI conformations are mapped onto a library of pharmacophores extracted from publicly 
available crystal structures of protein-ligand complexes. A fit score between the MOI's 
pharmacophores and those in the library is then calculated and N best fitting targets are 
suggested. The SDF file of VEDT structure downloaded from PubChem was converted to Tripos 
mol2 file using OpenBabel software (citation). The resulting mol2 file was submitted to 
PharmMapper server at http://59.78.96.61/pharmmapper. 
 
PASS (Prediction of Activity Spectra of Substances).  
PASS predicts biological activity of the MOI based on the Multilevel Neighborhoods of 
Atoms (MNA)
88
 structural descriptors of compounds and a training set of structure-activity 
relationship (SAR) data for over 60,000 chemical substances (SAR Base). For each biological 
activity, based on the similarity of MNA descriptors of the MOI and the substances in the SAR 
Base PASS outputs two probabilities, the probability of the MOI to exhibit the activity and the 
probability of the MOI to not exhibit the activity. To execute PASS prediction SMILES chemical 
identifier representing VEDT -
CC1=C2C(=CC(=C1)O)CCC(O2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C was extracted from 
PubChem entry for VEDT and submitted to http://www.pharmaexpert.ru/passonline/predict.php. 
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ProBiS (Protein Binding Sites Detection). 
 ProBiS identifies in the PDB (Protein Data Bank) proteins structurally similar to the 
user-supplied protein of interest (POI). The algorithm behind ProBiS server represents the entire 
proteins as graphs where vertices correspond to functional groups of surface amino acids and 
edges represent distance between these functional groups. Pairwise alignment of structural 
features of the POI and the proteins in PDB is then performed and results are displayed sorted by 
the statistical Z-scores, with the proteins most similar to POI displayed on top. PDB code for 
Estrogen Receptor β (ERβ) 1NDE89 and was used as the input for the ProBiS search. The choice 
of the above PDB code was based on the results of the VTS screen. 
 
Results 
The VTS screen of both VEDT and δ-tocopherol have resulted in a number of proteins 
that were hits for VEDT but not for δ-tocopherol (Table 4). 
Table 4. VEDT and δ-tocopherol VTS results. Hit - proteins into which an MOI docked with a 
score that outperformed the top 200 molecules of the calibration set. Hit* - identifies top hits; 
proteins into which an MOI docked with a score that outperformed the top 20 molecules of the 
calibration set. 
[Native ligand] Protein PDB Code 
VEDT 
Result 
δ-
tocopherol 
Result 
[Mon]Estrogen receptor beta 1NDE Hit* Not a Hit 
[ZEB]Cytidine Deaminase 1CTU Hit* Hit 
[MOF]Progesterone receptor 1SR7 Hit* Hit 
[Proflavin]Alpha-Thrombin 1BCU Hit Not a Hit 
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Table 4 (Continued) 
[CL3]Cell division protein zipA 1Y2G Hit Not a Hit 
[D91]Coagulation factor x- heavy chain 1WU1 Hit Not a Hit 
[SRL]Orphan nuclear receptor pxr 1ILH Hit Not a Hit 
[_U]Cytidine Deaminase 1AF2 Hit Hit 
[TTB]Retinoic acid receptor beta 1XAP Hit Not a Hit 
[442]Thyroid hormone receptor beta-1 1R6G Hit Not a Hit 
[L79]Retinoic acid receptor rxr-alpha 1RDT Hit Not a Hit 
[STR]Igg1-kappa db3 fab (light chain) 1DBB Hit Not a Hit 
[E1P]Peptidyl-prolyl cis-trans isomerase a 1W8M Hit Not a Hit 
[AO5]Methionine aminopeptidase 2 1R58 Hit Not a Hit 
[SDK]Cathepsin K 1AU0 Hit Not a Hit 
[FSN]Thrombin light chain 1OYT Hit Not a Hit 
[R11]Coagulation factor x 1G2M Hit Not a Hit 
[HEM]albumin (no iron) 1N5U Hit Not a Hit 
[ANO]Igg1-kappa db3 fab (light chain) 1DBK Hit Not a Hit 
[L10]Mitogen-activated protein kinase 14 1W82 Hit Not a Hit 
[AB8]Integrin alpha-I 1XDG Hit Not a Hit 
[FPP]Protein farnesyltransferase 1FPP Hit Not a Hit 
[IGN]Prothrombin 1K21 Hit Not a Hit 
[DHZ]Cytidine Deaminase 1CTT Hit Not a Hit 
[MSC]HIV-1 Protease 1D4J Hit Not a Hit 
[L08]Integrin alpha-I 1RD4 Hit Not a Hit 
{CI1031(Z34)]Coagulation Factor XA 1FJS Hit Not a Hit 
[BLN]Cathepsin s 1MS6 Hit Not a Hit 
[AIH]Estrogen receptor 1XP1 Hit Not a Hit 
[CMB]Blood coagulation factor xa 1LPZ Hit Not a Hit 
[RTR]Coagulation factor xa- heavy chain 1NFY Hit Not a Hit 
[EST]Estradiol receptor 1QKT Hit Not a Hit 
[STU]Tyrosine-Protein Kinase zap-70 1U59 Hit Not a Hit 
[Palmitate]Lipocalin Beta-Lactoglobulin 1B0O Hit Hit 
[AIU]Estrogen receptor 1XP6 Hit Not a Hit 
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Table 4 (Continued) 
[AAY]Integrin alpha-I 1XDD Hit Not a Hit 
[HYC]Type117 beta-hydroxysteroid 
dehydrogenase 1I5R Hit Not a Hit 
[CIU]Epoxide Hydrolase 1EK1 Hit Not a Hit 
[165]Prothrombin 1SB1 Hit Hit 
[CIU]Epoxide hydrolase 2- cytoplasmic 1VJ5 Hit Hit 
[HYF]Orphan nuclear receptor pxr 1M13 Hit Hit 
[337]map kinase 14 3CTQ Hit Hit 
 
According to VTS, ERβ (PDB code 1NDE) was a top hit for VEDT and while not being 
a hit for δ-tocopherol (Figure 12). 33 other proteins were also predicted as potential hits for 
VEDT but not for δ-tocopherol. This is consistent with some experimental findings that support 
binding of VEDT to ERβ.55,60 Moreover some patterns or at least consistencies may be observed 
by looking at the VTS hit list. In particular, a number of hormone and nuclear receptors can be 
seen in the proposed list of targets. This is not surprise however, as ProBis search for binding 
sites similar to the ERβ reveals that the binding sites of a number of proteins such as Rxr-like 
protein, retinoic acid receptor rxr-α, progesterone receptor and others are indeed quite similar 
(Table 5). 
PharmMapper prediction resulted in 300 proposed pharmacophores with those fitting the 
flexible alignment with VEDT ranked on top. These results were examined for consistency with 
the best VEDT hits from VTS screen. Ranked 51 was ERβ based on the pharmacophore derived 
from the PDB structure 1NDE, same structure that represented the best hit during VTS screen.  
 PASS prediction resulted in proposed 500 activities which VEDT statistically is more 
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Figure 12. Docked pose of VEDT as identified by the VTS. VEDT, colored in magenta forms 
hydrogen bonds (yellow dashed lines) with GLU 305 and ARG 346. 
Table 5. Results of the ProBis query based on the PDB ID 1NDE input structure. The list reveals 
structures in the Protein Data Bank that contain binding site similar to that of ERβ as represented 
by the structure under the PDB ID 1NDE. 
PDB ID Protein Name 
2j7y ESTROGEN RECEPTOR BETA 
3uud ESTROGEN RECEPTOR 
3ltx ESTROGEN RECEPTOR 
2e2r ESTROGEN-RELATED RECEPTOR GAMMA 
3mnp GLUCOCORTICOID RECEPTOR 
2q1h ANCCR 
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Table 5 (Continued) 
1xiu RXR-LIKE PROTEIN 
4fne STEROID RECEPTOR 2 
3k6p STEROID HORMONE RECEPTOR ERR1 
1g2n ULTRASPIRACLE PROTEIN 
4e2j ANCESTRAL GLUCOCORTICOID RECEPTOR 2 
3vhv MINERALOCORTICOID RECEPTOR 
1t7r ANDROGEN RECEPTOR 
2p1t RETINOIC ACID RECEPTOR RXR-ALPHA 
3ry9 ANCESTRAL GLUCOCORTICOID RECEPTOR 1 
1z5x ULTRASPIRACLE PROTEIN (USP) A HOMOLOGUE OF RXR 
3dzu RETINOIC ACID RECEPTOR RXR-ALPHA 
1sr7 PROGESTERONE RECEPTOR 
3plz FTZ-F1 RELATED PROTEIN 
1hg4 ULTRASPIRACLE 
1lbd RETINOID X RECEPTOR 
3eyb NUCLEAR HORMONE RECEPTOR RXR 
4iqr HEPATOCYTE NUCLEAR FACTOR 4-ALPHA 
2gl8 RETINOIC ACID RECEPTOR RXR-GAMMA 
2q60 RETINOID X RECEPTOR 
4j5x RETINOIC ACID RECEPTOR RXR-ALPHA, NUCLEAR RECEPTOR 
COACTIVATOR 1 
1lv2 HEPATOCYTE NUCLEAR FACTOR 4-GAMMA 
3dzu PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA 
3kmr RETINOIC ACID RECEPTOR ALPHA 
 
likely to exhibit than not. The results were ranked by the probability that VEDT exhibits a given 
activity. Similarly these results were examined for consistency with the VTS screen and  
PharmMapper prediction.  
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According to the PASS prediction there are several activities related either to estrogen 
modulation or the ERβ specifically (Table 6). 
Table 6. PASS prediction results. Predicted activities with relation to the estrogen modulation or 
action of ERβ. Rank – overall PASS rank of this activity by VEDT. Pa – Probability that VEDT 
exhibits the given activity. Pi – Probability that VEDT does not exhibit the given activity. 
 
 
 
 
According to PASS, among the estrogen related activities VEDT is likely to serve as 
estrogen antagonist with highest probability, followed by ERβ antagonist, followed by estrogen 
agonist, followed by ERβ agonist. Based on this result, VEDT is more likely to serve as an 
antagonist of estrogen and ERβ activity rather than their agonist.  
 
Discussion 
Consensus between Computational Studies 
Identification the potential molecular targets of VEDT has been attempted via a 
combination of molecular modeling (docking), chemoinformatics (SAR) techniques and 
bioinformatics in the form of binding site analysis, The results show consistency in identifying 
ERβ as a potential target of VEDT.  All three approaches VTS, PharmMapper and PASS have 
identified ERβ modulation as one of the potential activities of VEDT. In particular VTS has 
Rank Pa Pi Activity 
213 0,177 0,022 Estrogen antagonist 
234 0,148 0,024 Estrogen receptor beta 
antagonist 247 0,140 0,026 Estrogen agonist 
371 0,048 0,021 Estrogen beta receptor 
agonist 
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identified ERβ as represented by PDB ID 1NDE as a top target from a list of 1451 protein 
structures. Although PharmMapper and PASS algorithms operate on a substantially larger data 
space, still they were able to identify ERβ as a potential target, although didn’t rank it as high as 
VTS. Moreover PharmMapper exhibited consistency in preference towards the conformation of 
the ERβ  represented by 1NDE, hinting at possible antagonistic mechanism of action.60,89 The 
hypothesis of the antagonistic mode of action can also be favored based on the results of PASS 
which favored an antagonistic activity of VEDT towards ERβ than that of an agonistic. 
 
Consistency with Experimental Data 
 Although no experimental data was considered during the initial VTS screening of 
VEDT, subsequent literature search revealed that Comitato and colleagues had performed both 
the in vitro binding analyses and molecular docking studies to identify a high affinity interaction 
between VEDT and ERβ, a first evidence for such an association reported59,60. The consistency 
of experimental data with the computational approaches reported in this work is encouraging and 
gives validity to the use of tools such as VTS to probe for potential molecular targets of 
compounds with an unknown mode of action. In addition the use of the techniques described in 
this work allows for additional inferences regarding the precise modulating effect of the MOI on 
its target. Although Comitato and co-workers, based on the docking studies, favored an agonistic 
mode of action and seem to contradict the preference towards an antagonistic activity favored by 
our results, the combination of different approaches reported here can be beneficial in facilitating 
the investigation of the true mode of action of the MOI. 
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 Overall, the use of VTS, particularly in combination with other methods aimed at 
achieving similar goals via different approaches, is a viable strategy in helping identify potential 
targets of natural products and other chemical substances. Moreover utilization of bioinformatics 
approaches like ProBis can help gain additional insight into potential targets and help identify 
structures for further inclusion into the VTS and chemoinformatics screens. This multi-pronged 
consensus approach may prove especially valuable in cases where it is not feasible or otherwise 
prohibitive to conduct experimental studies to address this question. 
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CHAPTER FOUR: 
CHARMMING DRUG DESIGN DATABASE AND ADDITIONAL MODULES 
DEVELOPMENT 
CHARMMing Drug Design Database 
Database design considerations 
 Successful design of any data driven application relies heavily on its data storage and 
management backbone. Poor database design choices made at the inception of the project can 
significantly hinder the development at any point. Moreover, particularly damaging setbacks 
may result if poor design choices become apparent at later stages of the project life cycle. It 
seems difficult however to foresee all the use cases of the application, all the functionality and 
changes in specifications along the way. The dynamic nature of the application is especially 
characteristic of open source projects where the development contributions often take the project 
in the directions not initially intended or designed for.  
 To design a database that can efficiently and intuitively store data for a wide range of 
applications pertaining to a particular field one does not need to foresee all the use cases of the 
application. The database should not aim to achieve a particular usage profile. What database 
should do is to model the particular phenomenon or its targeted “universe” or a field which it is 
to represent. In the case of CHARMMing drug design database this “universe” is a field of drug 
design and discovery. Although in the case of CHARMMing, the field is narrowed specifically to 
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computer-aided drug discovery, the underlying data structures should ideally reflect the fact that 
this field is a part of larger field. 
 How does modeling the “universe” as a whole help design a better database for an 
application with particular usage scenarios? Any scenario that can be incorporated in an 
application and any use case will undoubtedly involve some aspects of the field that the 
underlying database is designed to model. It can also be said that a particular use case is not 
likely to involve all possible aspects of the field. At the same time however, a use case will never 
involve any aspects of fields completely outside of the one modeled by a database.  As an 
example of the former case, a rigid protein docking is not going to care about existence of 
multiple protein conformations. This doesn’t mean that there shouldn’t be a data structure that is 
designed to hold such information because flexible-protein docking, which is certainly within the 
realm of computer-aided drug discovery, will use this knowledge, thus the need for the 
representative data structures is necessitated. On the other end of the spectrum, the database 
designer can safely assume that there is no need to incorporate data structures storing the 
information regarding accounts receivables since accounting is rather different “universe” from 
computer-aided drug discovery and does not need to be represented in the database. 
 CHARRMing’s initial functionality already included modeling of proteins and the data 
structures that represent the target portion of the computer-aided drug discovery “universe” were 
already in place. To make the model of the entire “universe” more complete, the efforts to 
develop CHARMMing docking module included supplementing the existing database with data 
structures representing small molecule world and its relationship and interactions with the target 
world. Some additional data structures pertaining to targets were also added to more completely 
76 
 
represent the aspects of computer-aided drug discovery. The data structures to explicitly store 
information regarding the following entities were included: 
 Target data 
o Proteins, protein conformations, binding sites, residues, amino acids 
 Ligand/Substrate data 
o Ligands, fragments, de novo ligands, poses 
 Analysis 
o Molecular interactions, scoring, object attributes, metrics 
 Infrastructure 
o File and job management 
Additionally, although explicit data structures weren’t created, a link to the outside databases 
was established to fetch experimental results for the purpose of creating predictive models for 
(Quantitative) Structure-Activity Relationship ((Q)SAR) studies. 
 
Dynamic Relationship Schema 
 When designing a database for a project that is projected to have frequent addition of new 
modules and functionality over its lifetime it becomes a challenge to keep the complexity of the 
database in check while at the same time accommodating for the “unknown” future functionality. 
Specifically, number of tables storing new types of objects defined by new modules will grow 
linearly with the number of new objects. To keep flexibility in assigning attributes to object (i.e. 
to be able to assign any number of attributes to any number of object) many-to-many 
relationships will need to be defined between all the object types and their corresponding 
attributes. To accomplish this conventional database design approach dictates the need for a triad 
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of tables for each type of object to store the data pertaining to the object along with an indefinite 
number of attributes (Figure 13). 
 
Figure 13. The triad of tables dictated by traditional database design approach to define an 
object. In this case DockedPose, its attributes and a many-to-many relationship between them, 
described in the “Docked Pose Attribute Lookup” table. 
 
 The total number of tables required to store object-attribute data using this conventional 
approach is 3*N where N is a number of different types of objects. To curb the growth of the 
number of tables while, at the same time, allow for flexibility necessary for a project with a yet 
undefined future functionality an unconventional design approach was taken. In this approach 
here termed dynamic relationship all of the object types still reside in their respective tables. 
However all the attributes, independent of the possible object affiliations are defined in one table. 
In addition, and this is the key concept of the approach, all of the object-attribute associations are 
stored in a single table. To specify which object a particular attribute relates a separate field is 
used where the name of the table of the particular object type is stored (Figure 14). 
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Figure 14. The layout of the dynamic relationship schema. The objects (enclosed in the black 
frame) each reside in their respective tables as in the conventional design approach. The 
attributes all reside in a single table irrespective of their applicability to a particular type of 
object. ObjectAttributes table specifies the relationship between a specific attribute and a specific 
object by means of the ObjectID as dynamic foreign key to a table specified in the 
ObjectTableName field. 
 
The dynamic relationship schema design reduces the number of tables from 3*N to N+2, 
a three-fold reduction in the number of tables. This design allows linking any object with any 
attribute even if the link may seem less than intuitive during design time but becomes apparent 
during development of a particular module. Additionally, because many objects in 
CHARMMing have association with data residing outside of the database on a local file system 
as flat text files same dynamic approach was used to link objects with paths to files on disk. The 
dynamic relationship approach facilitates any type of future development within and outside of 
the scope of molecular modeling or computer-aided drug discovery as the design is non-specific 
yet highly flexible. 
. One potential disadvantage of dynamic relationship approach is that the queries to 
retrieve the data become more complicated. However, in cases where the database access is 
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handled by the ORM (object-relational mapping) as is the case with the Django engine which 
makes up the backbone of the CHARMMing web server, this is not an issue since the type of 
objects (i.e. the table name criteria) can be easily specified as an additional tern in the filter 
clause of the ORM API (application program interface) when interrogating the database. 
 
CHARMMing Fragment-Based de novo Drug Design Module 
Introduction 
 Another in silico approach that is part of the computer-aided drug design methodology is 
de novo ligand design. In this approach, unlike docking or virtual screening where a set of 
ligands are docked into the protein binding site, the ligands are constructed de novo. In other 
words, novel ligands are constructed as a result of this approach. There are a number of various 
approaches to this method. Atom-based design assembles or grows ligands atom by atom.
1
 
Fragment-based approach starts with a set of low molecular weight fragments and assembles 
novel ligands using them as building blocks. 
2–6
 There are advantages and disadvantages to these 
two approaches. Atom-based approach can sample a larger chemical space and result in a 
proposal of more diverse set of novel ligands. The disadvantage is however that the proposed 
ligands are more likely to be difficult to synthesize or even represent highly unrealistic 
structures.
3
 Fragment-based approaches, to a degree, address the problem of unrealistic structures 
by using fragments commonly found in known molecules and result in more drug-like structures. 
This however keeps fragment-based approaches largely within the confines of relatively well 
explored chemical space and sacrifices diversity and novelty for the synthetic feasibility. Still 
however, it remains a significant challenge to ensure that compounds proposed by de novo 
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approaches are readily synthesizable and much effort has gone into incorporating synthetic 
feasibility analysis into such approaches.
3–6
  
Fragment-based approaches, in turn utilize variety of methods to both generate the de 
novo structures and evaluate them in regards to their potential as a substrate for a particular 
target.  Two major components of the approach to the structure generation are ligand-based and 
structure-based. In ligand-based design, construction of the de novo ligand is guided by reference 
to other known ligand(s), pharmacophores or scaffolds.
7–12
 In the case of structure-based 
approach, the de novo design is guided primarily by the character of the binding site and 
evaluated solely based on the fragments’ and ligand’s interactions with the target.13–16 Logically, 
there exist a number of methods where the above two approaches are combined in one way or 
another. 
2,17–19
 There are certain trade-offs between choosing a particular approach to fragment-
based de novo design. Ligand-based methods somewhat alleviate the problem of synthetic 
accessibility of proposed ligands if novel ligands are forced by the evaluation conditions to be 
highly similar to known easily synthesizable structures. On the other hand, such an approach 
results the diversity and novelty of the proposed structures in comparison to a purely target 
structure-based approach. 
 Despite the lingering issue of synthetic feasibility of ligands generated by the fragment-
based approaches fragment-based de novo design methods have advantages over conventional 
virtual screening. Molecular fragments, although highly promiscuous when docked individually 
result in high ligand efficiency (LE). That is high predicted affinity (docking score) per heavy 
atom. If a novel compound is constructed from highly efficient fragments, the overall efficiency 
stays at a high level in a fully assembled ligand without the promiscuity of its individual building 
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blocks. The LE of novel ligands that result from such an approach is likely to be higher than that 
of an average ligand in a virtual screening library. 
 
Fragment-Based de novo Design Protocol Implementation in CHARMMing 
 Similarly to the docking protocol described in the chapter two, CHARMMing’s 
fragment-based de novo ligand design protocol is based on programs developed in the group of 
Prof. Caflisch at University of Zurich. 
2,20,21
 To serve as starting material, a library of 3,252 
fragments is pre-loaded into CHARMMing and is accessible to all users. This library is based on 
the Maybridge Hitfinder™ set (www.maybridge.com) on which public ligand library pre-loaded 
into CHARMMing is based as well. To generate the fragment set program DAIM 
(Decomposition And Identification of Molecules)
21
 was used with default settings. The 
fragments were then atom-typed and parametrized for compatibility with CHARMM 
Generalized Force Field (CGenFF).
22–25
  
De novo design protocol, outlined in Figure 15 consists of the following steps: 
1. Each fragment selected by user is docked into the user-specified binding site using 
the program SEED (Solvation Energy for Exhaustive Docking).
20
 More detailed 
mechanism of this fragment docking step is described in chapter two as this step is 
identical to the corresponding step of the CHARMMing’s fragment docking 
protocol. 
2. Program GANDI2 with a CGenFF compatible parameter file created and 
customized for this project is then used to join the docked fragments. The 
fragments are connected to each other in an iterative fashion using a set of pre-
loaded linker fragments and a procedure that grows the “connected” ligand by 
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randomly linking “disconnected” fragments and evaluating the fitness of the 
resulting structure using the island model genetic algorithm. All de novo ligands 
consisting of 2 and 3 fragments are evaluated in this manner. The fitness metric is 
a GANDI scoring function that incorporates protein-ligand van der Waals and 
electrostatic interactions as well, intra ligand interactions between fragments and 
linkers and penalties for unfavorable dihedral angles between newly connected 
fragments.
2
  
3. Top 20 ligands that have passed the energy cutoff are then atom-typed and 
parametrized to CGenFF standards using the program MATCH (Multipurpose 
atom-typer for CHARMM)
26
 for further processing by CHARMM program. 
Number of ligands to be kept for further processing is a user-modifiable parameter. 
4. Each ligand pre-processed in previous step is then incorporated into a ligand-target 
CHARMM compatible system and minimized using the adopted basis Newton-
Raphson (ABNR) for thousand steps while keeping the protein atoms fixed. The 
resulting CHARMM interaction energy values are recorded and the final pose of 
the ligand within the binding site of the target is also scored with SEED in its 
“evaluation only” mode. 
5. The consensus ranking approach used in the docking protocol and described in 
chapter two is utilized to assign final rankings to the newly constructed ligands. 
The consensus ranking is based on three scores GANDI score, CHARMM total 
interaction energy, and SEED total energy.  
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Figure 15. Flow chart of the CHARMMing’s fragment-based de novo design procedure. 
Procedure starts with a pre-loaded library of fragments which are first docked using SEED 
program. Then GANDI joins docked fragments to form new ligands. Top ligands are then atom-
typed and then parametrized using MATCH. Final series of steps involve minimization with 
CHARMM, evaluation with SEED and consensus ranking using GANDI score, CHARMM and 
SEED energies. 
 
The specification of binding site is also identical to the docking protocol and allows user 
to use a co-crystallized ligand, if present, to define a binding site, or define a custom binding site 
using a graphical point-and-click interface that is part of the CHARMMing’s drug design 
module. 
 The fragment-based de novo approach currently implemented in CHARMMing is purely 
target structure-based and the evaluation of each new ligand’s fitness is only dependent on the 
energetics of its interaction with the target and itself. GANDI however is a program that 
combines both structure-based and ligand-based construction and evaluation of the generated 
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ligands. The ligand-based criteria can be incorporated in a number of ways. A user can specify a 
template ligand which can serve as either a 2D or 3D reference during the de novo design 
procedure. In this case the similarity metric between each newly constructed ligand and the 
template is added to the GANDI scoring function with a user-defined weight coefficient. This 
allows the user to put high emphasis on the similarity aspect of the procedure. Similarly a 
pharmacophore definition can be supplied in place of the template ligand, analogously affecting 
the GANDI scoring function. The incorporation of the template and pharmacophore specification 
into the CHARMMing’s fragment-based de novo design interface is currently under 
development. 
 The interface of the CHARMMing’s fragment-based de novo design protocol is almost 
identical to that of the docking protocol (Figures 16 and 17) and incorporates a list of pre-loaded 
fragments on the job submission page as well as reflects the nature of the ligand construction 
protocol in the newly designed ligand names and scores. 
 
CHARMMing QSAR/SAR Module 
Introduction 
 A major component of computer-aided drug discovery is using known information to 
make informed decisions regarding the direction of a research campaign. Specifically, this 
involved building predictive models that infer a compound’s potential activity based on its 
features (mainly structural) and data available from other experiments. The models constructed 
in the context of this approach fall into two categories, structure-activity relationship (SAR)
28
 
and quantitative structure-activity relationship (QSAR)
29
. This type of predictive modeling has 
initially found most application during the lead optimization stage of the discovery campaign 
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Figure 16. CHARMMing’s fragment-based de novo design job submission page. This page 
differs from docking submission page in the list of starting molecules. Here pre-loaded fragment 
set consisting of 3252 fragments is presented as a starting material. 
 
 where a number of both pharmacodynamics and pharmacokinetic properties can be optimized 
by iteratively applying (Q)SAR models to lead compounds and their derivatives.
30–32
 Specifically 
potency, selectivity and specificity towards a particular target as well as absorption, distribution, 
secretion, metabolism and excretion collectively called ADME are among properties often 
sought to be improved using predictive modeling. Among the advantages of using (Q)SAR at 
early stages of the discovery campaign is the methodology’s ability to help identify undesirable 
compounds that are potentially highly promiscuous, toxic, or otherwise show lack of potential to 
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Figure 17. CHARMMing’s fragment-based de novo design job details/results page. This page 
differs from docking job details/results page in the naming of the newly constructed ligands and 
the scores involved in the consensus ranking. Here the de novo ligands reflect the naming of the 
genetic algorithm and GANDI score replaces docking’s FFLD27 score. 
 
be developed into a drug. This saves money by helping avoid high expenditures by discarding 
potentially problematic compounds at earlier stages of the drug discovery pipeline before 
committing substantial resources to the development and evaluation of drug candidates.
33–35
 
Predictive modeling have found wide use in industrial design, regulatory assessment of 
pharmaceutical agents, pesticides and other substances.
36,37
 Additionally, (Q)SAR models have 
found increasing use as an alternative to animal testing in cases where there is a push to actively 
steer away from methods that utilize animals for compound testing.
38,39
 Recently (Q)SAR 
modeling has been finding applications in conjunction with other computational drug discovery 
approaches such as virtual screening in addition to applications in substance risk assessment.
40
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However, the predictive performance and quality of (Q)SAR models in many respects lags 
behind other areas of machine learning applications and warrant improvements.
41
 
 As part of the efforts to address some of the shortcoming of (Q)SAR several SAR models 
have been developed based on such machine learning qualifiers as random forest
42,43
 and k 
Nearest Neighbor Simulated Annealing.
44
 These efforts helped lead to the identification of novel 
non-nucleoside chemical motifs as well as Candesartan, a drug used in treatment of hypertension 
and heart failure, for NS5B, hepatitis C virus RNA polymerase activity.
45
 This section describes 
implementation of the above and other models in the context of the development of the new 
(Q)SAR module of the CHARMMing web server.
46
 
 
 (Q)SAR Functionality of CHARMMing 
 (Q)SAR workflow in CHARMMing consists of two main components - model training 
and prediction. It is necessary to create a predictive model or use existing model before 
predictive analysis can be performed. 
 To train a model user can upload an SDF (structure data file) file that contains 
compounds’ structural information as well as other descriptors and metrics. To perform SAR 
prediction the training set needs to contain binary (Yes/No, Active/Inactive, etc.) activity metric. 
For QSAR models numerical activity values (e.g., IC50) need to be present in the training set. 
CHARMMing also provides interface to access PubChem Bioassay database that accepts a 
search criteria from the user and relays it to PubChem servers via PUG REST (Power User 
Gateway Representational State Transfer) and SOAP (Simple Object Access Protocol) 
interfaces.
47–52
 The search returns a list of assays with link to the detailed information on 
PubChem website and an option to download an SDF representing the structures with 
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corresponding structure/assay metrics. This file can then be directly submitted for model training 
into CHARMMing (Figure 18). List of models available through CHARMMing interface for 
training is listed in Table 7. Once the SDF is submitted, the user is asked to choose the property 
from the SDF (binary for SAR, numerical for QSAR) to use as a metric for model building. Once 
this selection is made the model building commences. Model training job is processed using 
CHARMMing’s job infrastructure utilized by all the other modules.  
Once training is complete the model is saved in the database and is only accessible to the 
user that has created it. User can view all the models created in the past along with the pertinent 
model information that among other things helps assess the quality of the model and its ability to 
produce reliable predictions. The screenshot of the model information screen in Figure 19 is an 
 
Figure 18. CHARMMing (Q)SAR model training file upload interface. Categorization models 
are used for SAR, Regression for QSAR. Currently available models with brief description are 
listed in Table 7. 
 
example of a Random Forest Categorization model and includes among other metrics the 
following measures of model quality – cross validation53, y-randomization54, area under the 
curve (AUC)
55
, precision and. Pearson correlation coefficient R
2
 is presented for regression  
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Table 7. List of predictive models available through CHARMMing. 
 
 
 
Figure 19. CHARMMing (Q)SAR model details screen. The screen presents user with the basic 
information about the job as well as common metrics to assess the predictive power and 
reliability of the model. Additionally, here user can run predictions based on this job. 
 
models. The model details screen is where a user can initiate prediction based on the model by 
uploading an SDF file with the test set structures. 
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The progress of any training or prediction job can be monitored in real time in a similar 
manner as other modules implemented in charming. Additionally SAR and QSAR tutorials are 
provided to introduce the user to the concept of predictive modeling as well as provide a guided 
walkthrough using the dataset used in the NS5B study.
45
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Computational Chemistry Education with CHARMMing 
Introduction 
 One of the primary purposes of CHARMMing is to serve as a bridge between the 
powerful capabilities of molecular modeling tools and a user that may not have capacity or 
technical expertise to operate these tools in their “raw” form. Aside from targeting academic labs 
and scientists that use CHARMMing to facilitate their research, the web interface provides a 
perfect means to serve another important need – chemistry education, and not necessarily just 
computational chemistry education. Basic chemistry concepts can be reinforced or approached 
from a different, possibly more engaging angle via the use of molecular dynamics.
56,57
 Most, 
especially non-commercial, molecular modeling software is not easy to use and requires 
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knowlede of program specific scripting syntax in additiona to some technical expertise. It has 
been argued however, that the problem of software complexity can be overcome by “friendly 
web interfaces” or via the use of bootable media with pre-installed software.58 CHARMMing, of 
course takes the former approach. Without the need to learn scripting languages or even look at 
somewhat intimidating program scripts, with a familiar point-and-click style of visual interface 
and engaging graphics CHARMMing has a potential to capture students that would be turned off 
by the complexity of molecular modeling. There are several factors that make CHARMMing 
espeicially attractive as an engaging educational tool: 
 Ability to perform many common molecular modeling and drug design tasks 
 Ability to monitor progress of jobs in real time 
 Ability to perform tasks in different order 
 Ability to visualize and graphically manipulate systems 
 Availability of tutorials for most tasks incorporated into CHARMMing 
To further increase usefullness of CHARMMing as an educational tool an interactive 
lessons module have been added to the web server and described in a series of papers.
59–61
 Here 
an overview of the lessons module is given along with exapmles of lessons incorporated into 
CHARMMing and their application as educational tools. 
 
Design and Implementation of CHARMMing Lessons Module 
 In order to increase CHARMMing’s lessons module’s value as an educational tool, 
several design considerations and functionalities were taken into account: 
 Provide a range of interactive lessons from the basic introductory to more 
advanced. 
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 Provide the students with the ability to track their progress in real-time. The 
student should be able to know where and at which step they are in a particular lesson, at 
as well as how does a particular lesson fit into a greater view of molecular modeling. 
 The module should identify mistakes made by the student during the course of the 
lesson, provide meaningful feedback and allow correction of such mistakes in order to 
proceed with the lesson plan. 
 Provide the user with ability to perform different taks to accomplish similar goals 
along with explanation of the differences and the applicability domain of each approach. 
 Provide the means for educators to create new lessons and workflows for 
students. 
CHARMMing incorporates primarily a structure centric workflow. That is, before any 
tasks can be performed a protein structure needs to be provided. This can be done via a query to 
PDB or a user specification. At the point of structure submission, a user is given the option to 
make the structure part of a particular lesson. Once the structure is associated with a lesson, any 
task that is performed with the structure is compared to the lesson plan for that particular lesson 
and the feedback to the user is provided. If, for example, user performs minimization on a 
structure where, according to lesson plan solvation was warranted first, the lesson progress 
indicates that solvation was not performed and the lesson cannot proceed until it is. Similarly if 
the task that is performed by the user is the correct task but with incorrect parameters (e.g. 
number of minimization steps is different from that in the lesson plan) the progress report notes 
that the minimization needs to be re-run because the parameter value was not correct. The 
overview of the overall lesson progress is updated in real time and is part of the navigation pane 
present on every page of the web site. The lesson progress also includes links to the details of 
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each step (Figure 20). Currently a total of seven lessons have been incorporated into 
CHARMMing: 
1. Lesson one: Introduction. Introduction to the basic features of CHARMMing as 
well as basic principles of structure preparation and molecular dynamics 
simulation. 
2. Lesson two: Simulation proteins. A lesson designed for a more thorough 
investigation of molecular dynamics of proteins. 
3. Lesson three: Enhanced sampling/Self-guided Langevin dyamics (SGLD). 
Intorduces students to a different flavor of protein dynamics to study 
conformational changes. 
4. Lesson four: Custom residue topology files (RTF), quantum mechanics/molecular 
mechanics (QM/MM). An introduction to the hybrid QM/MM simulations and a 
closer look at the files representing structure topology in CHARMM . 
5. Lesson five: Coarse grained modeling. Introduction to the representation of 
protein at a lower resolution by using “beads” representing groups of atoms and 
using this approach to investigate larger scale conformational changes in 
proteins.
60
 
6. Lesson six: Oxidation/Reduction Calculations. Allows students to investigate the 
process of electron donation and utilize the graphical interface to perform amino 
acid mutations.
61
 
7. Lesson seven: Molecular docking. An introduction to the concept of docking as a 
tool of the computer-aided drug design on an example of a self-dock. 
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In addition to the above lessons CHARMMing provides functionality to create new 
lessons by “recording” steps performed by a user into a lesson plan. If, for example, user checks 
“Start Lesson Recording” when initially uploading the structure, performs solvation, 
minimization and runs dynamics, all of these steps with the corersponding parameters for each 
task will be saved as a lesson plan and presented as a custom lesson. 
 In addition to the lessons module, a series of CHARMM/CHARMMing tutorials are 
available at http://www.charmmmtutorial.com. The tutorials cover all the concepts on that serve 
 
Figure 20. Examples of lesson progress bar. Three snapshots of a lesson progress of an 
“Introduction to Simulation” lesson. Student’s progress in the entire lesson is shown. Clicking on 
“Failed” link takes student to the details of that particular step with explanation of failure and 
steps necessary to resume the lesson. 
 
as a scientific base for CHARMMing and include walkthroughs of common workflows such as 
molecular dynamics simulations, docking studies, predictive modeling and others. Together with 
CHARMMing lessons these resources play a role beyond education. Most importantly they help 
ensure proper usage of CHARMMing and the tools it provides, highlight the importance of 
critically evaluating the results and promote proper scientific practices. 
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Conclusion 
 The wide range of functionality already available through CHARMMing and currently 
under development would not be possible without contribution from experts from a variety of 
fields within and outside of molecular modeling and computer-aided drug discovery. Moreover 
important design considerations at each step of development made it possible to unify and bring 
under one umbrella the diversity of the fields of molecular modeling and computer-aided drug 
discovery. The results of these efforts serve an important need and bring the power and variety of 
computational tools to those that have least access to them yet could gain the most from their 
use. With this however, the contributors to CHARMMing as well as to other open source 
scientific tools carry a burden of responsibility. Although one of the primary goals is that the 
fruits of their labor help make science more accessible, it is even more important that open-
source scientific resources ensure that the science facilitated by these tools is sound.  While 
making complex concepts more palatable to the user, it is imperative to make user realize the 
limitations of the approaches involved and the fact that results should often be taken with a grain 
of salt. CHARMMing contributors attempt to accomplish this mission by implementing only 
published and well-reviewed, well tested methods, by providing tutorials and lessons, by 
incorporating penalties into custom ligands whose structures are too “different” from existing 
force field parameters, by including confidence and performance metrics for (Q)SAR predictive 
models, by providing means to visually inspect the structures and monitor jobs output. The steps 
to ensure proper use of tools often require substantial effort. However it is the responsibility of 
the contributors to ensure that the methods implemented as part of these projects have solid 
scientific foundation. Moreover it is important that the interfaces and the workflows, however 
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friendly they may be, encourage critical evaluation of the results and promote the soundness of 
the scientific research. 
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APPENDIX A 
Permission to Print CHARMMing Fragment-Based Docking Paper 
 
 
Figure A1. Permission to print Fragment-Based Docking: Development of the CHARMMing 
Web User Interface as a Platform for Computer-Aided Drug Design 
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Permission to Print VTS Paper 
 
Figure A2. Permission to print Virtual Target Screening: Validation Using Protein Kinases 
103 
 
Permission to Print CHARMMing (Q)SAR Paper 
 
Figure A3. Permission to print Development and Implementation of (Q)SAR modeling within 
the CHARMMing web-user interface 
